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1. Summary 
 
The human immune response on either hypobaric hypoxia alone or combined with exercise at very 
high altitude has not been described in detail before. Studies implicate that hypoxia as well as 
exercise trigger both pro- and anti-inflammatory processes. This study, explores the relationship 
between biomarkers under hypobaric hypoxia in rest and under exercise conditions. This work is one 
part of a research leading to two different doctoral theses. One with focus on proinflammatory 
cytokines and chemokines, the other with focus on growth factors under the mentioned conditions. 
The twenty-five healthy volunteers participated in a series of resting and exercise trials both under 
normoxia and hypobaric hypoxia using a non-randomized, non-blinded design. Each trial included 
peripheral blood sampling at rest or before and 180 minutes after cessation of an incremental step 
test with 12 minutes of duration both at sea level and at 5050m (median barometric pressure was 
760mmHg and 563mmHg, respectively). Pro-inflammatory [IL-1beta, IL-2, IL-6, IL-8, IL-12p40, IL-1ra, 
sIL-2ra, IFNgamma, TNF-alpha, MCP-1, MIP-1alpha, MIP-1beta, and IP-10] and anti-inflammatory (IL-
4 and IL-10) biomarkers were assessed. Hypobaric hypoxia alone caused a significant increase in IL-
8, IL-1ra, sIL-2ra, TNF-alpha, MCP-1, and MIP-1beta and a significant decrease in IFNgamma, IL-
12p40, and MIP-1alpha. The same markers were measured before and after exercise both at sea level 
and at high altitude. IL-12p40 showed a significant increase at high altitude. Other biomarkers were 
unchanged. Hypobaric hypoxia is a potent trigger of changes in cytokine concentrations. Conversely, 
exercise seems to have minor effects on cytokine regulation. A trainings effect seems to be 
responsible for the unchanged cytokine plasma levels under the high altitude exercise test. 
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2. List of abbreviations 
 
IL-1beta   Interleukin 1 beta 
IL-2    Interleukin 2 
IL-6    Interleukin 6 
IL-8    Interleukin 8 
IL-12p14    subunit beta of interleukin 12 
IL-2ra    interleukin-2 receptor alpha 
sIL-2ra    soluble IL-2 receptor alpha 
IL-1ra    interleukin- 1 receptor antagonist 
IFNgamma   interferon gamma 
TNF alpha   tumor necrosis factor alpha 
MCP-1    monocyte chemoattractant protein-1 
MIP-1alpha   macrophage inflammatory protein alpha 
MIP-1beta   macrophage inflammatory protein beta 
IP-10    Interferon gamma-induced protein 10 
IL-4    interleukin 4 
IL-10     interleukin 10 
LPS    Lipopolysaccharide 
NGF    nerve growth factor 
ICAMS    intercellular adhesion molecule 
Ig M/G/A   immunoglobulin M/G/A 
GM-CSF    granulocyte macrophage colony-stimulating factor 
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APC    antigen presenting cell 
PAMP    pathogen-associated molecular pattern 
VCAM    vascular cell adhesion molecules 
BAL     bronchoalveolar lavage 
AMS     acute mountain sickness 
ARDS    acute respiratory distress syndrome 
HAPE    high altitude pulmonary edema 
MHC I/II   major histocompatibility complex I/II 
Fc region   fragment crystallizable region  
CD 80/86/40   cluster of differentiation 80/86/40 
Rpm    revolution per minute 
MFI    median fluorescent intensify 
COPD    chronic obstructive pulmonary disease 
ROS    reactive oxygen species 
TLR    toll like receptor 
HIF     hypoxia inducible factor 
LPS     lipopolysaccharide  
MNC    mononuclear cell 
PMA    phorbol-12-myristate-13 –acetate 
nf κB     nuclear factor kappa B 
LLS     Lake Louis Score 
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3. Introduction 
 
“I have not at all the feeling of having really got acclimatized  
which would certainly be the first necessary step toward improvement.” 
 From The Magic Mountain by Thomas Mann (1939) 
 
3.1. Humans and environmental extremes in the mountains 
 
Mountains exist on all continents and cover 27% of the earth´s surface. Human beings have to go to 
high altitude for different reasons. People settled down in high altitude since prehistoric time e.g. in 
the Andes [1]. 
Mountains and high altitude areas e.g. the Himalayans, the Andes, the Alps and the Atlas of Africa 
demand special adaptation of people. High altitude residents developed a physique that enables 
them to resist severe conditions since generations. They have to confront to extreme cold or extreme 
temperature variations, Hypoxia, oxygen lack and solar radiation, wind speed increase and humidity 
decrease [2]. 
In addition, high altitude residents who are adapted genetically, large numbers of people travel to 
high altitude for recreation, mountaineering, trekking, and skiing. Professionals like military 
personnel in Asia and in the latest time in Afghanistan and Kashmir as well as athletes or 
mountaineers in remote mountain areas are confronted with altitude problems, developing acute 
mountain sickness (AMS) and are in the focus of high altitude research. Especially the influence of 
hypobaric hypoxia and exercise in the immune system and the participation in the pathophysiology 
of AMS is the main part of research [1, 2]. 
The motivation of high altitude research is first to keep people in high altitude healthy and second to 
find out more about the complicated human physiology and pathology under hypobaric hypoxia. The 
high altitude model may be used as a paradigm especially in changes of the immune competence in 
cellular hypoxia as base for research in critical care medicine [3]. 
 
3. Introduction  
8 
 
3.2. The immune system 
 
The human immune system is an intricately regulated and interconnected complex network of 
circulating and fixed cells, lymphoid organs, cytokines and humoral factor that protect the human 
body from disturbing [4, 5]. The human defense consists of the innate and adaptive immune system 
that differ in speed and specificity in the immune reaction [5]. After a pathogen managed to pass 
through the mechanical, microbiological and physical barriers, which are part of the non-specific 
defense of the skin and natural surface barriers, it is confronted first by the cellular part of the innate 
system [4-6]. 
The innate immune system is a more basic system of cells and proteins that secures an immediate 
host defense [4, 5]. The adaptive immune response is a highly specialized cellular network acting via 
immunoglobulins in response organs (lymph nodes, spleen, and mucosa associated tissues). The two 
parts of the immune response are inseparable compounded and interact with each other [4, 5]. 
 
3.3. Cytokines 
 
Cytokines are small, non-enzymatic, non-structural proteins. Currently, about 130 members of the 
cytokine family are known [7]. Originally, they were called lymphokines and monokines in order to 
indicate their cellular origin [8]. 
They represent a multi-diverse family of polypeptide regulators of a low molecular weight which are 
produced throughout the body [9]. Through environmental challenges such as hypoxia, hypothermia, 
and pathogenic microorganisms, monocytes and macrophages are stimulated to release cytokines in 
order to mediate physiological adaptations to changes in homeostasis [10]. 
Cytokines are a heterogeneous group which involves interferons, interleukins, the chemokine family, 
growth factors, the tumor necrosis factor, and apokines [9]. 
They act in a hormone-like manner in nano- to picomolecular concentrations [8]. They are 
intercellular regulators and mobilize cells of the innate and adaptive immune system. Cytokines 
influence cell growth, cell death, angiogenesis, cellular development and repair processes in the aim 
of restoration of homeostasis [11]. They are secreted from different cell and act on other cells 
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fulfilling the definition of a hormone. However, unlike hormones which are produced in specialized 
primary tissues, cytokines are secreted ubiquitously. In general, every cell can both produce and 
respond to a cytokine, with the exception of erythrocytes [9]. 
 
3.3.1. Cytokine receptor and signaling pathways 
 
Cytokines act via a complicated network and are regulated by changing conditions imposed by other 
simultaneously acting cytokines. The net effect may be synergetic or contrasting. As mediators of 
inter-and intracellular communication, they are secreted by cells to stimulate other cells in a 
paracrine manner or to stimulate and alter their own function in an autocrine manner. While most 
cytokines are released into the extracellular interstitial fluid after biosynthesis, small amounts of 
cytokines are associated with the cellular membrane. Subsequently, extracellular binding of a 
cytokine to cell surface receptors initiates an intracellular signaling cascade eliciting nuclear events 
including regulation of proliferation, differentiation, and function of the cell [8]. 
 
Table 1 Cytokine receptors 
Cytokine family Members Receptor 
Hematopoietins IL-2,IL-3, IL-4 , IL-6, , IL-10, IFN 
alpha 
Cytokine receptor class 1 
TNF TNF-alpha, TNF-beta NGF/ TNF receptor 
Chemokines IL-8, MIP-1alpha, MIP-1beta, 
MCP-1 
Rhodopsinsuperfamily 
 
Beta-trefoil IL-1alpha, IL-1beta, IL-1ra Split tyrosine kinase/ IL-1 
receptor 
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3.3.2. Pro-inflammatory cytokines 
 
Cytokines are grouped due to their biological functions in different classes [12]. If they promote 
proinflammatory reactions, they are called “proinflammatory cytokines”, to demonstrate their role 
during infection and inflammation [12]. Proinflammatory cytokines are essential to start, accelerate 
and coordinate the immune response to protect the homeostasis against pathogens. They influence 
the cytotoxic effect and the humoral-, cellular- and allergic response [13]. 
 
3.3.3. Acute phase cytokines 
 
IL-1 is a paradigmatic cytokine illustrating the pleiotropic effect of cytokines. There exists a 
complicated network of interactions between family members and their receptors [14]. 
The IL-1 family includes three different peptides including IL-1beta, IL-1alpha and IL-1ra. IL-1ra is the 
antagonist of the IL-1 mediated effect.[14] Both IL-1alpha and IL-1beta, as their nomenclature shows, 
share similar proinflammatory activities. IL-1 is produced by activated macrophages from different 
sources (alveolar macrophages, Kupffer cells, adherent spleen and peritoneal macrophages), by 
peripheral neutrophils and T-and B-cells [14]. Together with IL-6 and TNF-alpha they are called “acute 
phase cytokines” [15, 16]. IL-1 stimulates the central nervous system as an endogenous pyrogen, 
interferes with metabolism via increased sympathetic tone and activates the production of acute 
phase proteins [14]. Triggers for the IL-1 stimulation are bacterial agents such as LPS( 
lipopolysaccharide) of the bacterial wall or nonbacterial stimulators such as hypoxia, thermal 
changes, radiation, other cytokines (TNF-alpha, IL-2, IL-3, IL-12) and multiple chemical 
attractants[14]. 
TNF-alpha is released by monocytes, macrophages, neutrophils, lymphocytes, natural killer cells, 
endothelial cells, astrocytes, and microglial cells. The main stimulators for TNF-alpha are LPS and 
endotoxin. Other stimulators include viral, fungal, and bacterial antigens, C5a anaphylaxin, immune 
complexes, and the synergistic IL-1 release of TNF-alpha. TNF-alpha can also trigger its own release. 
[17]. 
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TNF-alpha exerts a pleiotropic effect on a large number of target cells. The result of persisting TNF- 
alpha synthesis is cachexia. Via stimulation of metabolic enzymes, adipocytes and skeletal myocytes 
within the body undergo catabolism. Processes involved include glycogenolysis, lipolysis and 
increased protein turn over resulting in anemia and anorexia. This condition is present in cancer 
patients, acquired immune deficiency syndrome, parasite infections, and heart failure.[17]  
In septic shock, TNF-alpha and co-stimulatory factors such as IL-1 trigger the production of platelet 
activating factor, eicosanoids, and leukotriene which act as secondary effectors and lead to 
symptoms of shock. TNF-alpha acts synergetic with IL-1, affecting endothelial activation via leukocyte 
stimulation and binding to ICAMS (intercellular adhesion molecule) [18].This results in vascular 
leakage due to structural reorganization triggered by prostacyclin and endothelial derived factor. The 
structural change plays a role both in vasodilation and fluid sequestration as seen in shock. By acting 
as a growth factor, TNF-alpha triggers healing from inflammatory processes and stimulates 
fibroblasts for mesenchymal cell proliferation. In a cytotoxic effect, it mediates cell apoptosis and 
necrotic cell lysis. Referring to its name, some tumor cells are sensitive to this effect. Additionally, 
TNF-alpha affects the activity of natural cytotoxic cells. As a stimulator of immune response, 
activation of phagocytosis, leukocyte recruitment, and chemotaxis play a role in the innate immune 
response. TNF-alpha augments the production of superoxide anion and degranulation. Additionally, 
the production of IL-1 and IL-6 are stimulated. Finally, T-cells are activated which improves the 
immune response [12, 19-21]. 
 
The main sources of IL-6 are endothelial cells, fibroblasts, and monocytes/macrophages, especially 
during inflammation. Stimulators for IL-6 secretion by fibroblast and endothelial cells are IL-1 and 
TNF-alpha (co-stimulator). LPS is an additional trigger in monocytes. Recently, an IL-6 release from 
the contracting muscle during exercise was found [22]. It is known as the most potent stimulator of 
the acute phase reaction, acting via hepatocytes. Additionally, it influences B-cells and T-cells. In 
contrast, it also has anti-inflammatory effects [23-25]. 
As a major regulator of the acute phase reaction, the syntheses of acute phase proteins are activated 
via hepatocyte induction in synergy of IL-6 and IL-1. IL-6, compared to IL-1 and TNF-alpha, is the only 
stimulator of all acute phase proteins [24]. Thus, it plays a key role in the acute phase response. It 
initiates the leukocyte migration. IL-6 does not influence neutrophil infiltration but it stops the 
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accumulation [25]. The second role of IL-6 is to accelerate induction of apoptosis in neutrophils in 
order to end the first part of immune response. Hence,IL-6 is acting as a mediator between the innate 
and adaptive immune response [25]. 
IL-6 together with IL-4 and IL-5 activates B-cells to differentiate and leading to a sufficient secretion 
of immunoglobulins (IgM, IgG, IgA). While only activated B-cells are stimulated via IL-6, it has no 
influence on resting B-cells. In synergy with IL-3, IL-4, and GM-CSF (granulocyte macrophage colony-
stimulating factor), IL-6 stimulates multipotential hematopoietic stem cells [26]. 
T-cells in the thymus are co-stimulated by IL-6 and IL-1 for proliferation. Additionally, IL-6 
synergistically with IL-1 is necessary in the primary antigen dependent T- cell proliferation. Finally, T-
cytotoxic cells are activated by IL-6 [24]. 
 
3.3.4. Interferon family 
 
Characteristic of interferons is the ability to interfere with viral expansion [13]. The family is divided 
into two groups, type 1 (Interferon alpha and beta) and type 2 (interferon gamma) [6]. Group one 
has major antiviral activities; it is produced by fibroblasts and monocytes. A trigger mechanism leads 
to intracellular protection from infected viral RNA and up-regulation of MHC I, to enhance the 
destruction by cytotoxic T-cells from viral infected host cells [6]. 
Type 2 include interferon gamma. It was first mentioned as a secretion product of Th1 lymphocytes, 
CD4 helper cells, CD8 cytotoxic cells and neutrophil killer cells. It is the main cytokine of the TH1 
response [27]. 
Stimulation of MHC I was the first effect known for IFNgamma. It enables the CD8 cytotoxic cell to 
recognize the intracellular pathogen [27]. In addition, it triggers the release of IL-12 production from 
infected APC (antigen presenting cell). At the same time CD4 cell differentiation in the TH1 response 
is accelerated. Through all these actions IFNgamma links the innate to the adaptive immune response 
[27].  
IFNgamma mediated activation of macrophages causes an elevation in its biological activity [27]. The 
aforementioned link between the innate and adaptive immune system is important for the adequate 
antiviral response. Additionally, specific antiviral proteins are stimulated by IFNgamma. IFNgamma 
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acts as a chemokine, attracting leukocytes to the site of inflammation. Together with IL-1 and TNF-
alpha, chemokine activation is elevated by IFNgamma [27]. 
IL-2 and its receptor belong to the group of interferons. It plays a crucial role in T-cell activation and 
it is known as a T-cell growth factor and a stimulator in the cellular immune response [28]. 
In the pleiotropic sense, it is also responsible for down regulation of the T- cell response. 
Together with IFNgamma and IL-15, the Th1 response is supported by IL-2. The migration of the 
undifferentiated or partly differentiated T-cells to secondary lymphoid organs is especially triggered 
by IL-2. With IL-2’s influence, CD8 T-cells are accumulated and their differentiation is also completed 
in the lymph nodes [28]. Additionally, IL-2 is essential for priming T-cells and for sufficient 
development of T-memory cells [29]. In the case of a chronic infection, IL-2 promotes activation of 
induced cell death (apoptosis) to end the immune response and down regulate the T- cell response. 
Otherwise, a few activated T-cell are kept alive and will activate the host’s defense with a specialized 
T-cell unit and to recruit new undifferentiated T-cells [29].  
Beside the mentioned IL-2 receptor that is expressed on the surface of activated T-cells, a soluble 
receptor form is known. The soluble receptor consists of 2 subunits, the alpha chain and the beta 
chain, both are able to bind IL-2, and together they build a high affinity unit. The alpha chain is only 
expressed after a T cell or B- cell stimulation and its elevation gives a pattern of immune activity [30]. 
IL-12p40 is a subunit utilized by IL-12 and IL-23. They both have a heterodimeric structure and share 
the larger IL-12p40 units.IL-12 and IL-12p40 are often interchangeably used [13]. 
IL-12 is secreted by dendritic cells, Langerhans cells and mononuclear phagocytic cells as well as B- 
cells and mast cells. In synergy with IL-18 it is an activator of the Th1 cell response. This happens via 
differentiation of T-cytotoxic cells and stimulation of IFNgamma as the paradigmatic cytokine of the 
TH1 response.[13] During the innate immune response, APC in contact with LPS and pathogen 
associates molecules (PAMP) start to secret p40 and p35. This initiates an IL-12 secretion in APC´s 
that results in the secretion of IFNgamma and stimulation of T- cell differentiation [31]. 
With the first antigen contact at the port of infection, IL-12 is only triggered by PAMPs and is the first 
molecule secreted independently of cytokine stimulation. Therefore the immune response starts 
before presentation of the APC in secondary immune organs and via the interferone release, the 
adaptive response and specific T-cell answer is triggered.[31]. 
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3.3.5. Chemokines 
 
Chemokines belong to a small group of the cytokine family and are subdivided into different groups 
according to their cystein tertiary structure [7]. Their main task is the recruitment of leukocytes to 
the site of infection, a process called chemotaxis. Via stimulation of the leukocytes, chemokines 
augment the local immune response and potency. The migration of neutrophils is transendothelial 
along the gradient of the chemokine concentration.[6, 15, 32]. Parallel to cell recruitment, adhesion 
molecules in the vascular endothelium are up-regulated [32]. In order to concentrate the immune 
cells to the center of local immune response. Today, it is known that the task of chemokines is more 
complex and pleiotropic. They lead lymphocytes during hematopoiesis to sample antigens in 
secondary lymphoid tissue [7]. 
Simplistically, the function of the chemokine family is subdivided in pro-inflammatory and 
homeostatic actions. However; chemokines may have both functions (i.e. MCP-1) [33]. 
The currently known important chemokines are the monocyte chemoattractant protein-1 (MCP-1, 
CCL2), macrophage inflammatory protein-1alpha/ CCL3 (MIP-1alpha), macrophage inflammatory 
protein-1beta/ CCL4 (MIP-1beta) and interleukin 8 (IL-8, CXCL8) [13]. 
MIP-1alpha and MIP-1beta are released from mostly monocytes and macrophages by 
proinflammatory cytokines (IL-1beta, TNF-alpha and IFNgamma) and bacterial triggers like LPS [34]. 
Inhibition of MIP-1 secretion is transmitted via anti-inflammatory cytokines including IL-4, IL-10 and 
T-cells. MIP-1alpha augments the potency of the Th1 response by induction of the IFNgamma release 
in activated T-cells. MIP-1beta influences the adhesion of T- cells at the site of infection via vascular 
cell adhesion molecules (VCAMs) [34]. 
 
MCP-1 is produced primarily by monocytes; however, many other cells release MCP-1, too. In 
contrast to the other chemokines, the main purpose of MCP-1 is attracting monocytes to the site of 
inflammation and is one of the crucial parts of the innate immune response [35].It also activates and 
influences the chemotaxis of T-cells, monocytes, and natural killer cells [30]. MCP-1 is responsible for 
lymphocyte recruitment to lymph nodes, where T- cells undergo further differentiation [6]. The first 
contact between T-cells and antigens takes place in secondary lymphoid organs such as lymph nodes. 
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Stimulated by MCP-1, native T-cells (TH 0-cells) differentiate into Th2-cells. [6]MCP-1 and histamine 
release from eosinophils has been established [36]. 
IL-8 is produced by stimulated monocytes but not by tissue macrophages and T-cells. Mononuclear 
phagocytes release IL-8 upon stimulation by other pro-inflammatory cytokines including TNF-alpha, 
IL-1, IL-3, IL-7, GM-CSF, immune complexes and bacteria [37]. 
Mononuclear phagocytes are the main source for IL-8 secretion [13]. It is the most potent 
chemoattractant for neutrophils [13]. In addition, IL-8 release lysosomal enzymes from neutrophils 
in the context of the acute phase reaction and inhibits the histamine release from human basophils 
[37]. 
Interferon inducible factor 10 (IP-10, CXCL10) plays a crucial role in the development of the neural 
system.IP-10 influences embryogenesis and the development of the nervous system by recruiting of 
neural cells and inducing apoptosis in glial cells [38]. IP-10 mediated increase in cell growth is also 
seen in bronchial cells, astrocytes, glioma cells and some cancer cell lines [38]. The anti-proliferative 
and antiangiogenetic effect mostly influences tumor cells and inhibits cancer growth. It acts as a 
counterpart to the angioproliferative IL-8 to maintain balance between the two effects. Endothelial 
cells are the cells most affected [38]. 
 
3.3.6. Anti-inflammatory cytokines 
 
To regulate an adequate immune response, it is important to balance pro-and anti-inflammatory 
cytokines. After confronting the pathogen, a limitation of inflammatory response is necessary to 
prevent the body from its own destruction. An uncontrolled immune response can result in toxic 
shock with massive cellular damage [61]. In contrast to the majority of pro-inflammatory cytokines, 
IL-10 and IL-4 mainly exert anti-inflammatory effects. The lack of both cytokines results in total 
immunolysis during the proinflammatory response and it is responsible for multiple autoimmune 
diseases such as inflammatory bowel diseases and rheumatoid arthritis [61]. 
The crucial task of IL-10 is the inhibition of the acute inflammation response. This is accomplished by 
inhibiting the interacting proinflammatory cytokines. IL-10 directly inhibits IL-1 and TNF-alpha, the 
main activators of the acute phase response, as well as IL-1beta, IL-1alpha and the chemokine family 
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[62]. The inhibition works via two points of action. First is the inhibition of proinflammatory cytokines 
and the second is activation of the production in natural antagonist, like IL-1ra [61, 62]. 
IL-4 is a T-cell activator and influences B- cell growth .The main source of IL-4 is T- cells, especially 
activated CD4 T- helper cells. IL-4 influences Th2 cells in its pathway to maturation from primordial 
Th0 cell by up-regulation at the surface of Th2 cells, where IL-4 stimulates the cell maturation in the 
autocrine way. Other IL-4 sources are mast cells, eosinophils and basophiles, which release IL-4 via 
crosslinking of the Fc- receptor at the mast cell surface [63-65]. 
The mast cells, which fulfill a less specialized differentiation, contain IL-4 as a granule associated 
peptide in a preform and release IL-4 in the context of an allergic reaction. With the release of IL-4 
during the first antigen contact, the adaptive immune response is started in the antigen dependent 
priming of native CD4 cells and differentiation to Th2 cells and B cell proliferation is started [13, 65]. 
The Th2 response is important for stimulation of the humoral immune response and activation of B- 
cells. It negatively controls the Th1 response that defines the anti-inflammatory task of IL-4 [65]. 
IL-4 influences B-cell lymphopoiesis by activation, differentiation and proliferation of B-cells, as well 
as augmentation of the resting B-cell numbers. By stimulating MHC II, B7/CD 72 (CD80/CD86), CD 40 
and IgM the antigen presenting capacity of B-cells to T- cells is increased [64]. CD40 activated native 
B- lymphoid cells secret IgE in response to an IL-4 stimulation, which is a consequence of an isotype 
switch through deletional recombination in the B- cells DNA [66]. 
 
3.4. Hypoxia in high altitude 
 
Hypoxia is defined as the reduced partial pressure of oxygen in the inspiratory air that alters and 
influences the homeostasis of the body system. The relationship of altitude to partial O2 pressure is 
inverse, and a chain of physiological processes is initiated [39]. With higher altitude, the partial 
pressure of oxygen is reduced; however, the percentage of oxygen remains 20.93% in the 
atmosphere at every altitude [40, 41]. 
A reduced inspired oxygen level results in a pathway of adaption processes, first in organ systems 
and later in cellular mechanism. The path of the oxygen from the air through the lungs to the blood 
stream and later to the mitochondria of the cell is called the oxygen cascade. When there is a 
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reduction of inspired oxygen, the peripheral chemosensor in the carotid body detects the lack of 
oxygen and stimulates an increase in the respiratory rate, a process called ventilatory acclimatization 
[42-44]. 
At the cellular level, hypoxemia triggers the secretion of erythropoietin that augments the number 
of red blood cells to increase the number of oxygen carriers in the blood stream. 
On the molecular level, HIF-1 (hypoxia inducible factor-1) is released to trigger angiogenesis via 
cytokines and growth factors, to support continuing oxidative metabolism [42-44]. 
Acclimatization to hypoxia is mediated predominantly through HIF-1 and its subunits. HIF-1protects 
against tissue hypoxia at the molecular level and the HIF-1 pathway has been identified to regulate 
several hundred genes by direct or indirect modulation of gene expression. HIF-1 induced gene 
products modify various cell functions including metabolic functions and angiogenesis [42, 43]. All 
response mechanisms’ goal, whether it is hematopoietic, vascular or cardiorespiratory, are to 
maintain an adequate tissue oxygenation [45]. 
 
3.5. Hypoxia and cytokines 
 
Acute exposure to high altitude changes immunological parameters [39, 40]. Lymphocytes and 
phagocytes are known to show adaptation to hypobaric hypoxia via cytokine release [46]. 
Hypobaric hypoxia orchestrate the activity of immune cells. The T-cell mediated immune response is 
impaired more by hypoxia than natural killer cells that exhibit temporary changes [46]. In general, 
the phagocytic cells (monocytes, macrophages, neutrophils and mast cells) are stimulated by 
hypoxia, and are the first line of defense. There is a survival advantage to have immunological 
defenses stimulated by hypoxia from inflammation e.g. burns, trauma and pancreatitis [45]. Hypoxia 
stimulates phagocytosis, chemotaxis and increases neutrophils [46-48]. Hypoxia sensitized 
monocytes and T-cells respond with an elevation in the release of the proinflammatory cytokines like 
TNF-alpha, IL -1alpha, and IL-1beta [49]. 
The involvement of hypoxia triggered cytokine response as the cause for high altitude illness is a long 
held presumption. To date, there is no real evidence for cytokine involvement [49].In vitro hypoxia 
studies show that endotoxin stimulated mononuclear cells cause increased levels of IL-1alpha, IL-1 
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beta and TNF-alpha, and it is speculated that this is the origin of acute respiratory distress syndrome 
(ARDS) and high altitude pulmonary edema [16].TNF-alpha and the other proinflammatory cytokines 
have been found in increased concentrations in BAL (bronchoalveolar lavage fluid) in patients with 
high altitude edema and ARDS [50, 51]. 
IL-6 plays a key role in the acute phase response. The role of pluripotential IL-6 during hypoxia in the 
context of EPO (erythropoietin) stimulation and not in its inflammatory task [52]. A correlation of 
elevated acute phase proteins or other pro-inflammatory cytokines (IL-1, IL-1beta and TNF-alpha) 
and the co-stimulatory effect of IL-6 on EPO production in hepatocytes is known [52]. The signaling 
mechanisms remain unknown, however [53].Hypoxia is identified as a co-stimulator of the pro-
inflammatory cytokine production. The elevation in systemic proinflammatory cytokine levels is from 
local inflammation such as inflammation in the lung or the brain. The increase in inflammatory cells 
and cytokine levels are for the immune system to better react to the insult [54]. 
Local inflammatory reactions having systemic effects have been studied. In 1999, chemokines 
released from cerebral ischemia was first described by Bona et al [55]. In 2012, Cowell et al. [56] 
showed that MIP-1alpha was increased in cerebral hypoxic ischemic lesions five days after the 
hypoxic event in neonatal rat brains. This animal model showed a correlation of hypoxic time and 
increase in MIP-1 alpha. It is assumed that cerebral microglia and activated monocytes are secreting 
MIP-1 alpha [56]. 
Present research tries to link a coherence of systemic inflammation from alveolar macrophages is 
triggered by alveolar hypoxia. Not expectantly, systemic inflammation is not influenced by hypoxia 
in the tissue, but is influenced by the release of MCP-1 from macrophages playing a central role in 
systemic inflammation. MCP-1 is released into the blood stream by macrophages and travels to the 
target tissue to trigger mast cell degranulation. This is the first step of immune response due to 
hypoxia [36,57,58]. 
High altitude pulmonary edema (HAPE) and ARDS are associated with elevated levels of IL-8. The 
exact mechanism remains unclear, but it is speculated that IL-8 attracts leukocytes to the ischemic 
areas [59]. This theory is supported by the work of Karakurum et al. [60] who could prove that under 
hypoxic conditions endothelial cells produce IL-8 which triggers an increase of migration of 
neutrophils to the site of ischemia. Signal transmission is via nfκB-pathway. Further factors increased 
are IP-10, IFNgamma, TNF-alpha, and IL-2. 
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3.6. Physical Exercise and the immune system at high altitude 
 
Exercise and hypoxia are two different, independent stressors for the immune system. It is suggested 
that exercise under hypoxic conditions provokes a more pronounced immunological stress than 
exercise under sea level conditions. In addition to high altitude, exercise has a severe and transitory 
impact in the immune system and longs for a cooperation of the immunological, metabolic and 
sympatho-adrenal response to maintain the homeostasis [39]. 
Acute and chronic exercise has a transitory effect on the circulating immune cells. 
Neutrophils are increased immediately after exercise; a second delayed increase follows after a few 
hours. The first increase is catecholamine triggered and the second wave is assumed to be a cortisol 
dependent bone marrow release. Exercise stimulated hypoxia increases phagocytosis, chemotaxis 
and the reactive oxygen species (ROS) effect and is known as the hypoxic effect [61]. Circulating 
monocytes are increased about 2 hours after exercise and catecholamines are likely responsible by 
causing the demargination of immature monocytes. With a down-regulation of TLR (toll like receptor) 
there is a concomitant dependent decrease of IL-1, IL-6 and TNF-alpha [67, 68]. 
 
A post exercise lymphocytosis is well known and the increase is dependent on the intensity and 
duration of the exercise. The increase in T-and B- cells are mostly catecholamine dependent and 
normal levels return within 24 hours. The consensus of multiple studies have demonstrated an 
insignificant elevation in T-and B-cells [67-70]. 
Cytokine change due to exercise is different than the typical inflammatory cytokine release. The acute 
phase cytokines such as TNF-alpha and IL-1beta are normally not elevated after exercise. A different 
cascade in cytokine release compared to inflammatory cytokine pathways is assumed. IL-6 is one of 
the first cytokines to be released with exercise. Its source is the contracting muscle cells and they 
have a role in lipid metabolism. TNF-alpha, normally released after endotoxin stimulation during 
exercise, is generally decreased. This observation support the theory that the immune system is 
activated after exercise, but its role is more metabolic than immunologic. 
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Anti-inflammatory cytokines, such as IL-10 and IL-1ra, are generally elevated after exercise. In total, 
an anti-inflammatory milieu is produced and is influenced by catecholamines, cortisol, and growth 
factors that influence cytokine metabolism [69, 70]. 
 
3.7. Hypothesis 
 
The current work tries to illuminate the effect of hypobaric hypoxia on cytokine plasma levels 
measured by Luminex xMAP Multiplexing Technology under different circumstances. 
In detail, the following questions should be answered: 
 
1) Is there a change in cytokine levels in hypobaric hypoxia? 
2) Is there a change in cytokine plasma levels after the additional trigger exercise under 
normoxia and under hypobaric hypoxic conditions in high altitude? 
3) Is there an effect on cytokine release after a quick ascent from 5050m to 6035m? 
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4. Materials and methods 
 
All samples and entailing data sets have been acquired during both data collection sessions in Bangor 
[United Kingdom (UK)] in June 2008 and an international medical expedition (Hidden Valley 
Expedition 2008) in the Western Himalayan mountains (Dhaulagiri Circuit, Nepal) in September 2008. 
Both was organized by Medical Expeditions.  
The following methods are identical with the doctoral thesis of Sven Dietrich with focus on the change 
of growth factor under the mentioned conditions. 
Data presented in this study originates from a pool shared by the following cross-over study 
presenting complementary findings with respect to cytokine interaction during a high altitude (5050 
m) sojourn. 
 
4.1. Materials 
 
4.1.1. Equipment 
 
Sterican® 20-Gauge needle (B. Braun Melsungen AG, Melsungen, Deutschland), EDTA VacutainerTM 
(BD, Franklin Lakes, New Jersey, USA), Heparin VacutainerTM (BD, Franklin Lakes, New Jersey, USA), 
Eppendorf tubes of 1.5 ml (Eppendorf AG, Hamburg, Germany), pipette (Genex Β) (Genex 
Laboratories, Torquay, UK), centrifuge (Eppendorf MiniSpin) (Eppendorf AG, Hamburg, Germany), 
pulseoximeter (Nonin Onyx 9500) (Nonin Medical Inc., Plymouth, Minnesota, USA), barometric 
pressure wrist watch  (Suunto X3HR) (Suunto Oy, Vantaa, Finland), ratings of perceived exertion 
(Borg, 1982)  and mood (Feeling scale -5/+5: Hardy and Rejeski, 1989), SigmaStat and SigmaPlot 
(Systat Software, Inc., San José, California, USA), heart rate monitor (Polar S120) (Polar, Kempele, 
Finland), Eppendorf Thermomixer comfort (Eppendorf AG, Hamburg, Germany), Luminex 100 
(Luminex Corporation, Austin, Texas, USA), hemoglobin-photometer (HemoCue Plasma/Low Hb 
Photometer, Sweden/UK), centrifuge (HaematoSpin 1400, Hawksley, UK), hematocrit reader (Tube 
reader, Hawksley, UK), new Neubauer chamber. 
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4.1.2. Chemicals 
 
20-plex Premixed Human Cytokine Milliplex Map Panel Immunoassay (Cat. # SPRPMX21) including 
EGF, FGF-2, G-CSF, GM-CSF, IFNgamma, IL-1ra, IL-2, sIL-2ra, IL-4, IL-6, IL-8, IL-10, IL-12p40, IFNgamma-
induced protein (IP)-10, monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory 
protein (MIP)-1alpha, MIP-1beta, TNF-alpha, Human Cytokine/Chemokine Standard, Human 
Cytokine Quality Controls 1 and 2, Serum Matrix, Assay Buffer, Wash Buffer, Human Cytokine 
Detection Antibodies, Streptavidin-Phycoerythrin (Merck Millipore, Billerica, Massachusetts, USA), 
and Sheath Fluid (Luminex) 
 
4.2. Methods 
 
4.2.1. Study population 
 
The study formed one of a series completed on the “Hidden Valley Expedition 2008” to Nepal. The 
study was approved by both the Coventry Ethics Committee and the Nepal Health Research Council, 
and all participants provided written informed consent. 
All 25 subjects of the study were healthy moderately active expedition members. For further 
demographic data see table 1. 
Table 1 Demographic data 
The table shows demographic data of expedition members who participated in the present study. Values are expressed 
as mean (standard deviation), except for gender distribution (absolute numbers). 
M male, F female, BMI body mass index [body weight in kilograms per square meters (kg x m2)]. 
 Whole Group Group 1 
Resting 
Group 2 
Exercise 
Group 3 
Damphus Peak 
Sex, M : F 16 : 10 15 : 10 5 : 3 4 
Age, years 33.1 (± 11.74) 32.8 (± 11.33) 32.8 (± 8.44) 26.0 (± 3.91) 
BMI, kg x m2 23.33 (± 12.90) 22.48 (± 13.57) 27.12 (± 14.43) 14.25 (± 11.78) 
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4.2.2. Study design 
 
The study shows a non-randomized, non-blinded design with two parallel groups and an additional 
third group. The differing total numbers of participants in the 3 groups are due to the fact that 
individual subjects either took part in all groups or two or only one and due to the fact that some 
subjects only took part at sea level (69 m) but not at high altitude (5050 m). That is why for instance 
in group 2 as many as 10 subjects took part at sea level (69 m), but only 8 subjects at high altitude 
(5050 m). For further detail see table 2. 
 
Table 2 Number of participants in the 3 groups studied 
The table shows the distribution of participants and the strength of the different groups both at sea level (69 m) and 
high altitude (5050 m). Values are expressed as absolute numbers of participants. 
 Whole Group Group 1 
Resting 
Group 2 
Exercise 
Group 3 
Damphus Peak 
Total 26 25 10 4 
Sea level (69 m) 25 25 10 - 
High altitude 
(5050 m) 
18 18 8 4 
 
Group 1 members represent the reference group at rest. This group was comprised of 25 participants 
at sea level (69 m) and 18 at high altitude (5050 m). 
Group 2 members underwent an incremental exercise test and totaled to 10 at sea level (69 m) and 
8 at high altitude (5050 m). 
In addition, a third group of 4 participants underwent a one-day climb from Hidden Valley Base Camp 
(5050 m) to Damphus Peak (6035 m) and descending back to Hidden Valley Base Camp. 
The difference in altitude from ascent to Damphus Peak (6035 m) to descent to Base Camp (5050 m) 
totaled to 1970 meters. 
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In accordance with ethical approval from Coventry University Ethics Committee, participants gave 
their written informed consent to participate in the study in order to verify that they were fully 
informed of the study’s requirement and had been notified of and understood the possible risks. In 
addition, participants completed a health screen questionnaire prior to conducting each of the two 
trials. 
It has to be taken into account that subjects may or may not have participated in other double-
blinded studies of which one applied carbohydrate supplementation and the other inhaled Iloprost. 
 
4.2.3. Inclusion and exclusion criteria 
 
Inclusion criteria were normal hemoglobin and hematocrit values (quantified prior to commencing 
the expedition). Subjects were also asked to refrain from consuming food for at least 2-3 hours prior 
to exercise. All subjects were non-smokers over the age of 18 years. 
Exclusion criteria were a history of cardiovascular, respiratory, nervous, renal, liver, 
skeletal/muscular and metabolic disease. Additionally, none of the participants suffered from 
immunosuppression, was on any regular medication, or had suffered recently an allergic reaction. 
Other medical conditions were well controlled and individuals were free of symptoms at the time of 
the expedition’s departure. 
 
4.2.4. Data collection protocol 
 
The study consisted of two trials of data collection. The first trial was conducted at Bangor University, 
UK in July/August 2008 (69 m, barometric oxygen pressure (p02) 760 mmHg) and the second trial 
took place at Hidden Valley Base Camp, Nepal in October 2008 (5050 m, p02 550 mmHg). 
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4.2.5. Expedition itinerary 
 
The main route of ascent corresponded to the Dhaulagiri Circuit in the Western part of the Nepalese 
Himalayas. On the way to Hidden Valley Base Camp at 5050 m expedition members were exposed to 
various climatic conditions such as hot weather zones, humid subtropical climate, monsoon rain, and 
finally a permafrost zone above 3000 m. Expedition members were divided into four trekking groups, 
each of which departed on a different day.  
 
Table 3 and figure 1 show the complete expedition itinerary. 
 
Table 3 Expedition itinerary 
The expedition itinerary is outlined by showing starting and end points of each expedition day with 
corresponding altitudes. 
BC Base Camp, m meters 
Date 
(dd.mm.yy)
Day From To Start End Difference Start End Difference
02.10.08 1. Beni Babichar 826 970 144 914 900 14
03.10.09 2. Babichar Phedi 970 1007 37 904 885 19
04.10.08 3. Phedi Muna 1007 1701 694 880 826 54
05.10.08 4. Muna Jugapani 1701 1433 268 826 831 5
06.10.08 5. Jugapani Bogara 1433 2110 677 855 793 62
07.10.08 6. Bogara Bogara 2110 2110 0 792 793 1 Rest
08.10.08 7. Bogara Dobang 2110 2475 365 792 756 36
09.10.08 8. Dobang Dobang 2475 2475 0 759 758 1 Rest
10.10.08 9. Dobang Salagari 2475 3000 525 759 703 56
11.10.08 10. Salagari Italian Base Camp 3000 3606 606 705 683 22
12.10.08 11. Italian Base Camp Italian Base Camp 3606 3606 0 665 664 1 Rest
13.10.08 12. Italian Base Camp Japanese Base Camp 3606 4220 614 661 613 48
14.10.08 13. Japanese Base Camp Dhaulagiri BC 4220 4691 471 616 580 36
15.10.08 14. Dhaulagiri BC Hidden Valley 4691 5050 359 579 580 1
16.10.08 15. Hidden Valley Hidden Valley 5050 5050 0 580 512 68 Research
17.10.08 16. Hidden Valley Hidden Valley 5050 5050 0 554 512 42 Research
18.10.08 17. Hidden Valley Hidden Valley 5050 5050 0 NA 550 NA Research
19.10.08 18. Hidden Valley Hidden Valley 5050 5050 0 553 555 2 Research
20.10.08 19. Hidden Valley Hidden Valley 5050 5050 0 553 NA NA Research Damphus Peak (6035m)
21.10.08 20. Hidden Valley Hidden Valley 5050 5050 0 NA NA NA
22.10.08 21. Hidden Valley Yak Kharka 5050 3885 1165 NA 643 NA
23.10.08 22. Yak Kharka Marpha 3885 2670 1215 NA NA NA
24.10.08 23. Marpha Jomson 2670 2720 50 NA NA NA
Altitude (m)
Barometric Pressure 
(mmHg)
Route
Comments
Damphus Peak (6035m)
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Figure 1 Expedition itinerary 
The expedition in the Nepalese Himalayas started at Beni (826 m), went via the Dhaulagiri Circuit for 14 days in order to 
arrive at Hidden Valley Base Camp (5050 m). After 6 days of research the expedition went on and ended in Jomsom 
(2720 m). 
 
4.2.6. Collection of blood samples 
 
4.2.6.1. Set-up 
 
Baseline resting blood samples were taken from a population of 25 participants (10 women, 15 men) 
in Bangor (UK, 69 m) and of 18 participants (7 women, 11 men) in Hidden Valley Base Camp (Nepal, 
5050 m) who were all overnight fasted (minimum 8 hours fast). Participants remained in a seated 
position for 15 minutes prior to venipuncture from an antecubital vein by means of a 20-Gauge 
needle. A total amount of 6 ml blood was distributed into 1 EDTA and 1 Heparin VacutainerTM of 3 ml 
each. 
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Subjects who underwent an incremental step test were comprised of a population of 10 participants 
in Bangor (69 m) and 8 participants in Hidden Valley Base Camp (5050 m). Participants were fasted 
at least for 2-3 hours prior to the first and remained fasted until the last phlebotomy. 
After the first phlebotomy an incremental step test was undertaken. Each participant stepped on and 
off a 25 centimeter metal step over a period of twelve minutes in total subdivided into three intervals 
of four minutes each. An acoustic beeping signal indicated the step-frequency which was for the first 
interval 13 steps per minute, for the second 26 steps per minute, and with initiation of the third 
interval the beeping signal was turned off and the subject was asked to apply a step-frequency as 
high as possible. One entire stepping cycle consisted of putting one foot on the step with the first 
beep, followed by the second foot with the second beep, so that the participant was standing with 
both feet on the step. With beep three and four, the feet were brought down in the same fashion 
one by one. Every minute the leading foot was changed in order to prevent exhaustion of one 
particular lower limb. Immediately prior to and during exercise heart rate (Polar, S120), ratings of 
perceived exertion and mood (Feeling scale -5/+5) were recorded at minute intervals. Four more 
blood samples were taken directly after, 15 min, 90 min, and 180 min after cessation of exercise. A 
total of 30 ml of blood was collected per participant. 
A supplementary third group was formed by four subjects (all male) who undertook a one-day climb 
from Hidden Valley Base Camp (5050 m) to Damphus Peak (6035 m). After an overnight fast, blood 
samples were taken from participants at 03:30 a.m. (local time) prior to ascent and directly after 
return from the Damphus Peak summit. During their climb participants did not remain fasted. Meters 
covered on ascent and descent totaled to 1970. Duration of ascent and descent averaged to 12 hours 
(from 03:30 a.m. until 3:30 p.m.). 
 
4.2.6.2. Processing of Blood Samples 
 
Immediately after venipuncture the utilized EDTA VacutainerTM was aliquoted into 2 Eppendorf tubes 
of 1.5 ml each by means of a pipette (Genex B). Same procedure was applied to the utilized Heparin 
VacutainerTM. Within 30 minutes after venipuncture Eppendorf tubes were spun in a centrifuge 
(Eppendorf MiniSpin) for 10 minutes at sea level (69 m) and for 5 minutes at high altitude (5050 m) 
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at a relative centrifugal force of 12,000. Afterwards, plasma from the 2 EDTA and 2 Heparin aliquots 
was distributed to 6 and 2 Eppendorf tubes of 0.5ml each, respectively. 
 
4.2.6.3. Storage and Transport of Blood Samples 
 
After processing, blood samples were sealed in plastic bags and kept at -26° Celsius (C) in a freezer. 
At Hidden Valley Base Camp (Nepal, 5050 m), the portable freezer was insulated with a styrofoam 
case and cooled via a gas cartridge on the day of descent. Transportation of the freezer by foot to 
the nearest town with electrical supply for cooling took 8 hours. During transportation a remote 
sensor in the freezer allowed for real time temperature readings and re-cooling via a gas cartridge 
provided stable temperatures of at least -10° C or below. Subsequently, samples were transported 
by plane from Nepal to the UK, where samples from the first trial were added and finally sent via air 
mail to the laboratory in Homburg (Germany). 
 
4.2.7. Immunoassay 
 
In order to analyze specimen Luminex xMAP Multiplexing Technology was employed. Following 
cytokines were measured simultaneously: IL-1beta, IL-2, IL-6, IL-8, IL-12p40, IL-1ra, sIL-2ra, 
IFNgamma, TNF-alpha, MCP-1, MIP-1alpha, MIP-1beta, IP-10 and anti-inflammatory (IL-4 and IL-10). 
Additionally, the growth factors from Sven Dietrichs study were analyzed. 
 
4.2.7.1. Luminex xMAP Multiplex Technology 
Luminex allows simultaneous analysis of exact quantities of a large number of small-volume samples. 
It is a highly specific, sensitive, and reliable assay. Luminex is based on flow cytometry and employs 
as the key principle the fluorescent color coding of microspheres (polystyrene particles) allowing 
their identification and precise correlation with their respective population through optical analysis. 
Through combination of red and infrared fluorescent dyes 100 (102) different fluorescent color tones 
are created. One unique bead class is made up by one microsphere dyed with one of the 100 different 
fluorescent color tones and its specific capture antibody. Specific reaction partners (analytes) bind to 
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the microsphere´s capture antibody. The resulting complex (bead + capture antibody + analyte) is 
recognized by a detection antibody and subsequently labeled with so-called reporter molecules. The 
median fluorescence intensity of the reporter molecule is then used to quantify the amount of 
analyte bound to the bead. In this manner, a single sample of a volume as small as 25 μl can be 
incubated with up to 100 different bead classes at the same time on a 96-well-microtiter plate [71, 
72]. 
After the binding reaction is completed, microspheres are suctioned from the microtiter plate. While 
two lasers are directed at the particle stream, mirrors direct fluorescence discriminator signals 
emitted from microspheres and detection signals emitted from reporter molecules to detectors. 
Figure 2 shows the set-up of the bead (microsphere) technology. Photodiodes classify the 
microspheres and detect side scatter signals of the particles, which allows determination of the 
particle size and exclusion of fluorescent contaminants or microsphere aggregates (e.g., doublets) 
from the results, respectively. A special laser excites the fluorescent dye of the reporter molecules 
and the intensity of the emitted light allows for quantification of the analyte bound to a particular 
microsphere. Finally, optical signals are translated into digital signals. With the Luminex analysis 
system, up to 20,000 events per second can be amplified, processed and recorded.  
 
 
 
Figure 2 The bead (microsphere) technology of Luminex 
Luminex employs as the key principle the fluorescent color coding of microspheres (polystyrene particles) allowing their 
identification and precise correlation with their respective population through optical analysis. One unique bead class is 
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made up by one microsphere dyed with one of the 100 different fluorescent color tones and its specific capture 
antibody. Specific reaction partners (analytes) bind to the microsphere´s capture antibody. The resulting complex (bead 
+ capture antibody + analyte) is recognized by a detection antibody and subsequently labeled with a so-called reporter 
molecule. While two lasers are directed at the particle stream, mirrors direct fluorescence discriminator signals emitted 
from microspheres and detection signals emitted from reporter molecules to detectors. Photodiodes classify the 
microspheres and detect side scatter signals of the particles. The median fluorescence intensity of the reporter 
molecule is then used to quantify the amount of analyte bound to the bead. Optical signals are finally translated into 
digital signals.  
 
 
4.2.7.2. Assay 
 
Before analysis, samples were prepared as recommended by the manufacturer’s instructions (see 
figure 3). Premixed antibody-immobilized beads were sonicated for 30 seconds and vortexed for 1 
minute. Quality controls 1 and 2 were generated by adding 250 µl deionized water, mixing and 
vortexing the vials (rest before use: 5-10 min) and pipetting them into test tubes. At room 
temperature 30 ml of wash buffer were diluted with 270 ml deionized water. 1.0 ml of deionized 
water was mixed into the bottle containing lyophilized Serum Matrix (rest before use: 10 min). Adding 
250 µl deionized water resulted in human cytokine standard (10,000 pg/ml). Working standards were 
generated by serial dilutions of the standard dilution (10,000 pg/ml). Five test tubes were filled with 
200µl of Assay Buffer (0 pg/ml). 50 µl of the 10,000 pg/ml standard was added to tube 1 (= 2000 
pg/ml). 50 µl of tube 1 was added to tube 2 (= 400 pg/ml). 50 µl of tube 2 was added to tube 3 (= 80 
pg/ml). 50 µl of tube 3 was added to tube 4 (= 16 pg/ml). 50 µl of tube 4 was added to tube 5 (= 3.2 
pg/ml). 
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Figure 3 Assay preparation 
Before analysis, samples were prepared as recommended by the manufacturer’s instructions. 1.0 ml of deionized water 
was mixed into the bottle containing lyophilized Serum Matrix and 250 µl deionized water was added. The resulting 
human cytokine standard (10,000 pg/ml). Working standards were generated by serial dilutions of the standard dilution 
(10,000 pg/ml). Five test tubes were filled with 200 ìl of Assay Buffer (0 pg/ml). 50 µl of the 10,000 pg/ml standard was 
added to tube 1 (= 2000 pg/ml). 50 µl of tube 1 was added to tube 2 (= 400 pg/ml). 50 µl of tube 2 was added to tube 3 
(= 80 pg/ml). 50 µl of tube 3 was added to tube 4 (= 16 pg/ml). 50 µl of tube 4 was added to tube 5 (= 3.2 pg/ml). 
pg pictogram, ml milliliter, µl microliter 
 
After adding 200 µl of Assay Buffer into each of the 96 wells the microtiter plate was sealed and 
mixed on a plate shaker (Eppendorf Thermomixer comfort) at 500 revolutions per minute (rpm) for 
10 minutes at room temperature (20-25° C). Assay Buffer was then removed and 25 µl of each 
Standard and Quality Control solution were pipetted into the respective wells. Assay Buffer was used 
for the 0 pg/ml standard (background). Each sample well was filled with 25 µl of Assay Buffer and 25 
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µl of Serum Matrix solution was added to each of the Background, Standards, and Quality Control 
wells. Eventually, 25 µl of each sample was pipetted into the appropriate wells. The bottle containing 
the premixed beads was vortexed and 25 µl of the bead mix were added to each well. 
After incubation (60 min at 20-25° C) on the plate shaker the fluid phase was removed from the 
microtiter plate and each well was washed 2 times with 200 of Wash Buffer. 
Before a second incubation process (30 min at 20-25° C) began, 25 µl of detection antibodies were 
added to each well. After pipetting 25 µl of Streptavidin R-Phycoerythrin into each well, a third 
incubation period (30 min at 20-25° C) on the plate shaker began. All fluid was removed from the 
microtiter plate and each well was washed 2 times with 200 µl of Wash Buffer. Each well was then 
filled with 150 µl of Sheath Fluid, the plate was put on a plate shaker for 5 minutes, and ultimately 
inserted into the Luminex 100™ IS. The median fluorescent intensity (MFI) data was saved and 
cytokine concentrations in samples were calculated. 
 
4.2.7.3. Software 
 
Data was analyzed using Luminex IS 2.3 and both MFI and calculated concentration values were 
reported for each analyte. 
 
4.2.8. Statistical method 
 
Statistical analysis was performed using SigmaStat 3.1 (Systat Software, Point Richmond, CA, USA). 
Differences between sea level (69 m) and high altitude (5050 m) values as well as between pre-
exercise and post-exercise values were analyzed using the Wilcoxon test. Values of p < 0.05 were 
considered statistically significant. Results are presented as median (Min; Max). We considered 3.2 
pg/ml, the lowest dilution on the standard curve, to be the lower limit of detection. 
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4.2.9. Additional data 
 
While leucocyte counts were obtained by means of microscopic visualization in a new Neubauer 
chamber, data about differential counts was provided kindly by the laboratory of Heartlands hospital 
(Birmingham, UK). 
Hemoglobin content of blood samples was measured by means of a hemoglobin-photometer 
(HemoCue Plasma/Low Hb Photometer). By means of both a centrifuge (HaematoSpin 1400) and a 
hematocrit reader (Tube reader), hematocrit measurements were obtained. 
 
Data sets from the participants´ data collection booklets were provided by the University of Bangor 
(Wales, UK). Data include cold symptoms, Bristol stool scale, resting heart rate, arterial oxygen 
saturation, barometric pressure, and the Lake Louise Score (LLS). 
Cold symptoms in the last 24 hours were reported by the participant in person in the evenings 
throughout the entire sojourn. For each of the following items participants gave subjective score 
points with 0 = none, 1 = mild, 2 = moderate, and 3 = severe: sneezing, runny nose, blocked nose, 
sore throat, cough, chilliness, and malaise. 
Gastrointestinal voiding was self-reported on a daily basis by employing the Bristol Stool Scale 
(number of motions per day and consistency of motions on a 1–7-point Likert scale). 
Resting heart rate and arterial oxygen saturation was recorded both in the mornings while fasted and 
seated for 10 minutes and in the evenings while seated for 10 minutes by means of a pulse oximeter 
(Nonin Onyx 9500). Barometric pressure was read from a wrist watch (Suunto X3HR). 
The LLS (Lake Louis Score)was filled in by the participant in person in the mornings throughout the 
entire sojourn. For each of the following five symptoms participants gave subjective score points in 
increasing severity from 0 to 3: headache, gut symptoms, fatigue/weakness, dizzy/lightheaded, 
difficulty sleeping (see table 4). 
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Score Headache 
Gastrointestinal 
symptoms 
Fatigue/ 
weakness 
Dizziness/ 
lightheadedness Difficulty Sleeping 
0 None None None None Slept as well as usual 
1 Mild 
poor appetite  
or nausea 
Mild Mild 
Did not sleep as well as 
usual 
2 moderate 
moderate nausea 
or vomiting 
Moderate Moderate 
Woke many times,  
poor night’s sleep 
3 Severe 
severe nausea  
and vomiting, 
incapacitating 
Severe Severe Could not sleep at all 
 
Table 4 Lake Louise Score 
The Lake Louise Score uses five symptoms, each scoring from 0 to 3 with increasing severity in order to detect AMS. 
 
 
The diagnosis of AMS is based on a rise in altitude within the last four days and the application of the 
scoring system according to the LLS. In order to diagnose AMS, headache is obligatory and at least 
one other symptom of the LLS has to be present (gastrointestinal symptoms, fatigue/weakness, 
dizziness/lightheadedness, difficulty sleeping). Finally, a total score of 3 or more from the 
questionnaire confirms the diagnosis of AMS. 3 to 5 points mean mild AMS and scores of 6 and above 
signify severe AMS  
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5. Results 
 
Results for cytokines and additional parameters like blood cell counts and saturation were obtained after 
statistical calculation. 
According to the hypothesis, the results are subdivided into three parts. 
At first, data from resting subjects was analyzed and sea level values were related to high altitude values. 
Additionally, data from subjects who undertook a standardized incremental exercise test was utilized to 
check values before exercise against values 180 minutes after cessation of exercise, both was confirmed 
at sea level and high altitude. At last, data obtained from a one-day climb totaling to an altitude 
difference of 1970 meters was evaluated to compare values before ascent with values after descent. 
As the major finding, proinflammatory cytokines (sIL-2ra, IFNgamma, TNF-alpha), especially chemokines 
(IL-8, MCP-1, MIP-1alpha, MIP-1beta) showed in general a significant changes predominantly when 
comparing sea level values with high altitude values. 
Compared to sea level values, high altitude plasma levels were elevated in the following cytokines: IL-8, 
IL-1ra, sIL-2ra, TNF-alpha, MIP-1alpha and MCP-1. A decrease in high altitude plasma levels was found in 
IFNgamma, IL-12p40 and MIP-1alpha. 
There was no major impact on cytokine levels through exercise both at sea level and at high altitude. 
The additional short term altitude difference of 970 m had no impact in cytokine plasma levels.  
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5.1. Group 1 (Resting at Sea Level versus High Altitude) 
 
Following table shows all data from participants that were at rest both at sea level and at high altitude. 
Variable (units) n=25 Sea Level High Altitude p value Rise ↑/ Fall 
↓ 
IL-1beta 6.345 ± 7.466 10.84 ± 18.884 NS ↑ 
IL-2 6.566 ± 12.54 6.6 ± 16.401 NS ↑ 
IL-4 3.178 ± 0.108 4.958 ± 6.493 NS ↑ 
IL-6 13.001 ± 34.257 13.492 ± 38.112 NS ↑ 
IL-8 5.786 ± 2.528 10.186 ± 4.693 <0.001 ↑ 
IL-10 27.086 ± 
108.326 
28.332 ± 
110.762 
NS ↑ 
IL-12p40 48.711± 81.042 33.382 ± 64.249 0.011 ↓ 
IL-1ra 19.139 ± 43.677 36.991 ± 80.163 0.002 ↑ 
sIL-2ra 40.974 ± 94.385 118.477 ± 
192.003 
<0.001 ↑ 
IFNgamma 19.561 ± 17.214 11.691 ± 9.087 0.001 ↓ 
TNF-alpha 8.328 ± 4.154 11.929± 6.613 0.002 ↑ 
MCP-1 255.493± 
64.942 
353.895± 
179.509 
0.001 ↑ 
MIP-1alpha 26.974± 27.287 19.864± 17.028 0.015 ↓ 
MIP-1beta 33.025 ± 20.668 65.951± 58.777 <0.001 ↑ 
IP-10 571.147± 
257.908 
665.549± 
291.548 
NS ↑ 
Leucocytes/µl 3475 ± 1627,41 4414.47 ± 
2292.58 
NS ↑ 
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Lymphocytes (%) 49 ± 13.34 40.29 ± 13.46 0.048 ↓ 
Monocytes (%) 2.81 ± 2,01 4.06 ± 2.51 NS ↑ 
Neutrophils (%) 45.43 ± 11,93 55.35 ± 12.87 0.022 ↑ 
Eosinophils (%) 3.53 ± 3,56 1.58 ± 0.9 NS ↓ 
Basophils (%) 3 ± NA NA NA NA 
O2 Saturation (%) 95.04 ± 4.80 79.82 ± 8.6 <0.001 ↓ 
pO2 (mmHg) 760 ± 0 554.25 ± 0.44 <0.001 ↓ 
Hgb (g/L) 141.08 ± 16.11 157.13 ± 17.94 <0.001 ↑ 
Hct (%) 39.83 ± 5.20 44.2 ± 4.6 NS ↑ 
BMI 23.28 ± 2.75 23.69 ± 3.56 NS ↑ 
Mean ± standard deviation rounded values of 25 subjects are shown. 
IL-1beta interleukin (IL) 1 beta, IL-12p40subunit beta of interleukin IL-12, sIL-2 ra soluble IL-2 receptor alpha, IFNgamma 
Interferone gamma, TNF-alpha tumor necrosis factor alpha,MCP-1monocyte chemoattractant protein-1, MIP-1 alpha 
macrophage inflammatory protein 1 alpha, IP-10interferone inducible factor 10, O2oxygen, pO2 barometric oxygen 
pressure, Hgb hemoglobin, Hcthematocrit, BMI body mass index, NS not significant, NA not available 
 
Table 5 Cytokines, differential counts and additional data of resting subjects at sea level versus 
high altitude. 
 
In subjects that were at rest, significant changes occurred when comparing sea level data with values at 
altitude (5050m) in the following proinflammatory cytokines: IFNgamma, IL-12p40, TNF-alpha, sIL-2ra. 
There were no marked changes in the other proinflammatory cytokines including IL-2, IL-4, IL-6, and IL-
1beta. 
Significant change within the anti-inflammatory group occurs in IL-1ra, while IL-4 and IL-10 were not 
significantly elevated. 
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Significant changes in chemokines at high altitude were seen in IL-8, MIP-1beta, MIP-1alpha, and MCP-
1. Analysis of differential counts showed significant changes in neutrophils and lymphocytes. 
Insignificantly altered were leucocytes, monocytes, and eosinophils. Additionally, O2 saturation and 
partial oxygen pressure along with hemoglobin counts did show significant changes. However, neither 
BMI, nor hematocrit changed significantly. 
 
Variable (units) n=25 Sea Level High Altitude p value Rise ↑/ Fall 
↓ 
IL-8 5.786 ± 2.528 10.186 ± 4.693 <0.001 ↑ 
IL-12p40 48.711 ± 81.042 33.382 ± 64.249 0.011 ↓ 
IL-1ra 19.139 ± 43.677 36.991 ± 80.163 0.002 ↑ 
sIL-2ra 40.974 ± 94.385 118.477 ± 
192.003 
<0.001 ↑ 
IFNgamma 19.561 ± 17.214 11.691 ± 9.087 0.001 ↓ 
TNF-alpha 8.328 ± 4.154 11.929± 6.613 0.002 ↑ 
MCP-1 255.493± 
64.942 
353.895± 
179.509 
0.001 ↑ 
MIP-1alpha 26.974± 27.287 19.864± 17.028 0.015 ↓ 
MIP-1beta 33.025 ± 20.668 65.951± 58.777 <0.001 ↑ 
Lymphocytes (%) 49 ± 13.34 40.29 ± 13.46 0.048 ↓ 
Neutrophils (%) 45.43 ± 11,93 55.35 ± 12.87 0.022 ↑ 
O2 Saturation (%) 95.04 ± 4.80 79.82 ± 8.6 <0.001 ↓ 
pO2 (mmHg) 760 ± 0 554.25 ± 0.44 <0.001 ↓ 
Hgb(g/L) 141.08 ± 16.11 157.13 ± 17.94 <0.001 ↑ 
Mean ± standard deviation rounded values of 25 subjects are shown. 
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IL-8interleukin (IL) 8, IL-12p40subunit beta of interleukin IL-12, sIL-2 receptor alphasoluble IL-2 receptor alpha, IFNgamma 
Interferone gamma, TNF-alpha tumor necrosis factor alpha,MCP-1monocyte chemoattractant protein-1, MIP-1 
alphamacrophage inflammatory protein 1 alpha, MIP-1 beta macrophage inflammatory protein beta, O2oxygen, pO2 
barometric oxygen pressure, Hgbhemoglobin 
Table 6 Significant changes of cytokines, differential counts and additional data of resting subjects at sea level versus 
high altitude 
 
In resting subjects, a rise of most of the cytokines was observed at high altitude when compared to 
values at sea level. The proinflammatory cytokines, TNF-alpha (p <0.002) and sIL2-ra (p<0.002), and the 
chemokines MCP-1 (p =0.001), MIP-1beta (p <0.001) and IL-8 (p<0.001) showed a significant rise at high 
altitude. 
IFNgamma (p<0.001) and the chemokines MIP-1alpha (p<0.0015) decreased significantly. 
The anti-inflammatory cytokine IL-1ra was the only with significant elevation in plasma level at altitude 
(p<0.002). 
Analysis of differential blood counts showed significant changes shown by a decrease in lymphocytes 
(p=0.048) and an increase in neutrophil counts (p=0.022) at high altitude. Finally, significant results of 
additional data include a decrease in partial oxygen pressure (p<0.001) and oxygen saturation (p<0.001), 
while hemoglobin levels were significantly elevated (p<0.001) at high altitude. 
Additional parameters such as BMI did not change significantly nor hematocrit. However, O2 saturation, 
partial oxygen pressure decreased significantly, when hemoglobin was elevated in high altitude. 
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5.2. Group 2 (Exercise) 
 
Following table shows all data of subjects who underwent an incremental exercise step test both at sea 
level and at high altitude. 
Variable 
(units)n=8 
Sea Level High Altitude 
 Pre 180min 
post 
p ↑/↓ Pre 180min post p 
        
IL-1beta 6.279 ± 
5.408 
6.373 ± 
5.888 
NS ↑ 16.74 ± 
26.707 
6,248 ± 5,65 NS 
IL-2 4.604 ± 
3.372 
3.589 ± 
1.08 
NS ↓ 3.622 ± 
0.782 
3.152 ± 0.134 NS 
IL-4 3.132 ± 
0.191 
3.2 ± 0 NS ↑ 3.2 ± 0 3.544 ± 0.972 NS 
IL-6 9.794 ± 
8.832 
10.169 ± 
8.704 
NS ↑ 8.489 ± 
6.046 
 
7.57 ± 7.02 
NS 
IL-8 6.46 ± 
3.681 
6.25 ± 
2.962 
NS ↓ 6.945 ± 
2.425 
6.562 ± 2.302 NS 
IL-10 7.114 ± 
7.34 
7.054 ± 
7.582 
NS ↓ 7.694 ± 
9.172 
7.137 ± 7.538 NS 
IL-12p40 58.06 ± 
81.747 
54.844 ± 
79.743 
NS ↓ 30.969 ± 
47.65 
42.055 ± 
58.566 
0.0
31 
 
IL-1ra 32.918 ± 
47.106 
34.211 ± 
50.737 
NS ↑ 39.868 ± 
59.089 
39.829 ± 
61.341 
NS 
sIL-ra 22.025 ± 
39.217 
34.07 ± 
67.94 
NS ↑ 47.377 ± 
77.395 
55.39 ± 81.64 NS 
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IFNgamma 22.05 ± 
21.331 
20.77 ± 
18.28 
NS ↓ 17.031 ± 
17.093 
9.766 ± 5.944 NS 
TNF-alpha 7.652 ± 
5.142 
6.967 ± 
4.299 
NS ↓ 7.925 ± 
3.537 
6.735 ± 2.345 NS 
MCP-1 253.903 ± 
57.399 
214.316 ± 
62.444 
NS ↓ 349.311 ± 
159.12 
257.021 ± 
80.782 
NS 
MIP-1alpha 33.885 ± 
26.316 
34.165 ± 
20.164 
NS ↑ 27.28 ± 
19.885 
18.471 ± 
15.737 
NS 
MIP-1beta 29.067 ± 
10.411 
27.9 ± 
11.194 
NS ↓ 32.903 ± 
14.081 
32.368 ± 
13.858 
NS 
IP-10 428.356 ± 
156.268 
412.285 ± 
156.359 
NS ↓ 547.191 ± 
394.251 
548.722 ± 
352.491 
NS 
Leucocytes/µl 4281.25 ± 
1613.766 
6818.75 ± 
1933.342 
0.0
16 
↑ 4256.25 ± 
752.348 
8543,75 ± 
3485,422 
0,0
08 
Lymphocytes 
(%) 
45.143 ± 
16.807 
38 ± 12.617 NS ↓ 44.5 ± 
9.739 
39,75 ± 
10,348 
NS 
Monocytes 
(%) 
3.125 ± 
1.553 
5.333 ± 
4.131 
NS ↑ 3 ± 2.673 2,333 ± 1,033 NS 
Neutrophils 
(%) 
49 ± 14.306 56.5 ± 
15.476 
NS ↑ 51 ± 8.485 58,125 ± 
10,602 
NS 
Eosinophils 
(%) 
2.857 ± 
4.18 
2 ± 1.549 NS ↓ 2.4 ± 1.14 1 ± 0 NS 
Basophils (%) NA NA NA NA NA NA NA 
O2 Saturation 
(%) 
96 ± 1.069 NA NA 85.313 ± 6.665 NA 
pO2 (mmHg) 760 ± 0 NA NA 553.75 ± 1.035 NA 
Hgb (g/l) 140.25 ± 
19.219 
142.875 ± 
18.78 
NS ↑ 167.333 ± 
16.042 
173 ± 15,427 NS 
Hct (%) 41.25 ± 
5.308 
40.75 ± 2.403 NS ↓ 48.5 ± 
4.243 
NA NA 
BMI 23.63 ± 0.984 NA NA 26.232 ± 4.995 NA 
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AMS 0 ± 0 NA NA 0 ± 0 NA 
 
Mean ± standard deviation rounded values of 8 subjects are shown. 
IL-1beta, interleukin (IL) 1 beta,IL-2 , interleukin 2,IL-1ra, interleukin 1 receptor antagonist, IL-12p40subunit beta of 
interleukin IL-12, sIL-2 ra soluble IL-2 receptor alpha, IFNgamma Interferone gamma, TNF-alpha tumor necrosis factor 
alpha,MCP-1monocyte chemoattractant protein-1, MIP-1 alpha macrophage inflammatory protein 1 alpha, IP-
10interferone inducible factor 10, O2oxygen, pO2 barometric oxygen pressure, Hgbhemoglobin, Hcthematocrit, BMI body 
mass index, NS not significant, NA not available, ↑ increase, ↓ decrease 
Table 7 Cytokines, differential counts and additional data of exercising subjects at sea level and high 
altitude 
 
Two factors measured in exercising subjects presented values of statistical significance. While we could 
show a significant increase after 180 minutes after exercise at high altitude for IL-12p40, it was not 
different in a significant magnitude at sea level. Secondly, the leucocyte count showed a significant 
increase 180 minutes after exercise both at sea level and high altitude. 
 
5.2.1 Sea level at rest versus 180 minutes post exercise 
 
There was no significant change in any of the cytokine at sea level after 180min.post exercise. 
Only the leucocytes showed a significant elevation (p = 0.016). 
 
5.2.2. High altitude pre versus 180 minutes post 
 
At high altitude no significant changes occurred in all cytokines in plasma levels when compared before 
and 180 minutes after cessation of exercise except IL-12p40 (p=0.0031). However, leucocytes showed 
significant increase (p= 0.008). 
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5.3. Group 3 (Damphus Peak) 
 
No significant changes, neither in cytokines, nor in differential counts nor in additional data, could be 
shown after intense exertion while climbing to Damphus Peak at 6035m. The difference in altitude from 
ascent to descent totaled to 1970 meters. 
 
Variable (units)n=4 Pre Post p value Rise ↑/ 
Fall ↓ 
IL-1 beta 4.055 ± 1.037 4.270 ± 1.196 NS ↑ 
IL-2 3.200 ± 0.000 3.105 ± 0.190 NS ↓ 
IL-4 3.200 ± 0.000 3.200 ± 0.000 NS → 
IL-6 4.210 ± 2.033 6.277 ± 2.636 NS ↑ 
IL-8 8.465 ± 3.969 8.170 ± 0.739 NS ↓ 
IL-10 6.758 ± 4.600 5.298 ± 2.471 NS ↓ 
IL-12p40 4.982 ± 3.565 4.063 ± 1.725 NS ↓ 
IL-1ra 57.403 ± 88.926 59.750 ± 102.388 NS ↑ 
sIL-2ra 166.938 ± 
205.895 
154.355 ± 10.176 NS ↓ 
IFNgamma 14.833 ± 10.157 14.435 ± 11.178 NS ↓ 
TNF-alpha 8.183 ± 2.374 7.218 ± 2.575 NS ↓ 
MCP-1 586.735 ± 
376.423 
409.728 ± 
191.185 
NS ↓ 
MIP-1alpha 17.038 ± 6.099 18.795 ± 11.087 NS ↑ 
MIP-1beta 47.830 ± 20.418 31.470 ± 12.255 NS ↓ 
IP-10 583.018 ± 
110.445 
450.520 ± 
119.833 
NS ↓ 
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Leucocytes/µl 5025 ± 1330.1 9987.5 ± 3416.23 NS ↑ 
Lymphocytes (%) 49.25 ± 8.921 24 ± NA NA NA 
Monocytes (%) 7 ± 1.633 3 ± NA NA NA 
Neutrophils (%) 39.5 ± 6.028 72 ± NA NA NA 
Eosinophils (%) 4.25 ± 1.708 1 ± NA NA NA 
Basophils (%) NA NA NA NA 
O2 Saturation (%) NA NA NA NA 
pO2 (mmHg) 553 ± 0 553 ± 0 NS → 
Hgb(g/L) 170.5 ± 11.121 175 ± NA NA NA 
Hct (%) 39.83 ± 5.20 44.2 ± 4.6 NS ↑ 
Leucocytes/µl 5025 ± 1330.1 9987.5 ± 3416.23 NS ↑ 
Mean ± standard deviation rounded values of 4 subjects are shown. 
IL-1 beta interleukin (IL) 1 beta, IL-12p40subunit beta of interleukin IL-12, sIL-2ra soluble IL-2 receptor alpha, IFNgamma 
Interferone gamma, TNF-alpha tumor necrosis factor alpha,MCP-1monocyte chemoattractant protein-1, MIP-1 alpha 
macrophage inflammatory protein 1 alpha, IP-10 interferon inducible factor 10, O2oxygen, pO2 barometric oxygen 
pressure, Hgbhemoglobin, Hcthematocrit, BMI body mass index, NS not significant, NA not available 
 
Table 8 Nonsignificant changes of cytokines, differential counts, and additional data after a one -day climb 
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6. Discussion 
 
The goal of this research is to investigate if hypobaric hypoxia influences pro- and anti-inflammatory 
cytokine and chemokine plasma levels and if exercise has any additional effect. 
The exposure to high altitude is a well-known environmental stress with physiological consequences, 
with the major stressor being hypobaric hypoxia. Nevertheless cytokines are pleiotropic and their 
production, stimulation and release is influenced by multiple external and internal stimuli like 
temperature, changes in pathogen exposure, stress hormones, exercise , and circadian rhythm. These 
facts are the crux of in vivo investigations that researchers attempt to master for an interference free 
study environment. 
Prior investigations tried to measure the change in behavior and activity of immune cells under different 
environmental conditions. Measuring cytokine levels is one way to show changes in immunocompetent 
cells in a hypoxic condition [46, 73]. 
In acute mountain sickness triggered by hypobaric hypoxia as a causative agent, inflammation has long 
been suspected as a second trigger for its pathogenesis. Nevertheless, most investigations failed to 
demonstrate a correlation [54, 74]. 
The change in cytokine production is a way of measuring the cells adaptation to the hypoxic stimuli. 
Studying the effects of hypoxic conditions will contribute to our emerging understanding of the 
physiological changes observed in hypobaria and hypoxia, as well as in malignancy and in inflammation. 
Exercise as an additional stressor failed to demonstrate any observed plasma level changes between sea 
level and high altitude [46]. 
What makes this research remarkable is the data comes from in vivo hypobaric hypoxic condition in high 
altitude, whereas most studies to date used normobaric hypoxic chambers. It is one of the widest 
biomarker studies under hypobaria and exercise as additional stimulator [75]. 
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6.1. Proinflammatory cytokines under hypoxic conditions 
 
To date research postulates an augmentation in the production of proinflammatory cytokines under 
hypobaric hypoxia as it is common in pathophysiological conditions like malignancy, strokes, wound 
healing and sepsis [76].  
A long standing hypothesis is the increase in proinflammatory cytokines and chemokines lead to 
manifestations of AMS triggered by changes in the blood brain barrier homeostasis that results in the 
cerebral edema seen in HAPE. Nevertheless there is no proof of mentioned biomarker involvement in 
the pathogenesis [49]. 
The major finding of this study is an elevation of TNF-alpha, IL-12p40, sIL-2ra, IL-1ra and the chemokines 
under hypobaric hypoxia, while IFNgamma decreased significantly in this condition. 
While Julian et al.[49] failed to show changes in TNF-alpha under hypobaric hypoxia under similar 
conditions, this study confirmed significant increases in TNF-alpha after exposure to high altitude. 
Compared to the biomarker study of Julian et al.[49] the probands were not treated with 
immunomodulation medication as acetazolamide and dexamethasone, which are known to reduce 
plasma levels of TNF-alpha. 
The results are in agreement with both human (from bronchoalveolar lavage) and animal studies [77, 
78].TNF-alpha augmentation was also reported in rat brains after intermittent hypoxia [79]. It has also 
been found to be elevated in hypoxia-mediated clinical conditions such as patients with obstructive sleep 
apnea and cardiovascular remodeling after a hypoxic trigger resulting in right ventricular hypertrophy in 
lung fibrosis [80, 81]. In the work of Smith et al.[82], TNF-alpha levels change when measured in acute 
and chronic hypoxia in mice. TNF-alpha is augmented in hypoxic conditions and triggers a complicated 
pathophysiological process, inducing a hypoxia mediated pulmonary vasoconstriction and initiating an 
IL-6 release in animal models after chronic intermittent hypoxia (10 % pO2 , Duration of 21 days)[82].  
This study failed to show an increase in IL-6; however recent work presents the novel finding. There are 
significant changes in TNF-alpha under hypobaric hypoxia. 
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Several studies showed a TNF-alpha increase during hypoxia in alveolar cells and a similar correlation in 
ARDS and HAPE is assumed [50,51, 83].The data is controversial as Svenson et al.[84] couldn`t find any 
change in proinflammatory cytokines especially, TNF-alpha in the BAL of probands after a rapid ascent 
to 4559 m or in HAPE patients. However, they failed to measure plasma cytokine levels. Hempel et al. 
[83] found under LPS stimulation of human alveolar macrophages under hypoxia (02< 0.05%) an 
augmentation of TNF-alpha release, compared to room air. 
In Summary, the elevation of TNF-alpha during hypoxia could be seen as an experimental model for other 
hypoxic pathological conditions such as rapid tumor growth, in wounds, and the development of ARDS 
and AMS [85]. 
Since it is already known in pulmonary artery hypertension, hypoxia caused by lung fibrosis that leads to 
right ventricular hypertrophy is triggered by a TNF-alpha mediated process. Further investigations could 
lead to therapy with a TNF-alpha antagonist after the role of TNF-alpha in hypoxia induced 
pathophysiological processes is better defined[16]. 
In conclusion, TNF-alpha is augmented while the corresponding cytokines, IL-1 and IL-6 remain 
unaffected. Unfortunately we could not correlate an involvement of TNF-alpha in high altitude 
associated cachexia and anorexia as it is typically seen in tumor patients. The BMI decreased 
insignificantly, but this could be due to an elevation in muscle mass and a decrease in body fat after the 
ascent to Hidden Valley Base camp[18]. 
IL-6, one of the best investigated proinflammatory cytokine did not show a change under hypobaric 
hypoxia. This finding is in agreement with Pavlicek et al.[86]and Svenson et al. [87]. 
Currently, the data is controversial. Hartmann, Schoene, Klausen and Mazzeo et al. found elevated 
plasma levels after different altitude exposure time (> 2 days) [42, 52, 54, 88]. 
Elevated levels in IL-6 under hypoxia are correlated to a nonspecific inflammation which might be an 
expression of organ prone hypoxia triggered inflammation. Alveolar endothelial cells, cardiomyocytes 
and leukocytes are known to release IL-6 in response to hypoxia [54]. A correlation of hypoxic sensitive 
organs and cytokine release in response to the development of AMS is assumed [52, 54]. In animal and 
in vitro cell studies, the effect of hypoxemia as an individual trigger of IL-6 release has been shown 
6. Discussion 
48 
[89].IL-6 is known to stimulate EPO production in hepatocytes during hypoxia [53]. IL-6 seems to fulfill 
local proinflammatory, adaptive and a pathophysiological task during hypoxia. The probands of this 
study underwent a 15 day trip in altitude to get adapted to the final altitude of 5050m. During this time, 
probands were already exposed to two different stimuli, altitude and physical exercise by walking. 
Hartmann et al. [54] tried to differentiate between active and passive ascent to high altitude in different 
altitudes. No change of cytokines plasma level was found in the higher altitude, which supports the 
assumption of an acclimatization effect [54]. The collected data (high altitude baseline sample) was 
already influenced by active ascent. To date unfortunately, no studies of a long-term sojourn in high 
altitude and IL-6 levels are known. 
For future investigations, blood samples should be taken during the ascent to the maximum research 
altitude to verify any cytokine change. 
Nevertheless, this study and the comparable work of Julian et al. [49]challenge the question of IL-6’s 
participation as a key proinflammatory cytokine in hypobaric hypoxia. Both did not show an elevation of 
IL-6 in hypoxic conditions, however Julian et al. reported elevated levels after a nine hour exposure at 
an altitude of 4875m in AMS resistant probands. The reason is still unknown and needs further 
investigations. 
In analogy to Fritzenwanger et al., Klokker et al. and Julian et al.[45, 49, 90] found no change in IL-1beta 
plasma levels in hypobaric hypoxia, simulated hypoxia in a decompression chamber and under real 
altitude conditions in vivo. 
Conflicting data was presented by Ghezzi et al. [16]. An increase in IL-1beta and IL-1alpha under hypoxia 
was found. But instead of hypobaric hypoxia, Ghezzi et al.[16] exposed MNC in cell culture to anoxia 
(FiO2 0%), which presumably exerted a stronger hypoxic effect. Dziurla et al.[91] created a hypoxic cell 
culture in vitro of stimulated CD4 cells and found increased levels of IL-1beta, IL-10 and IL-8.  
Becker et al.[10] investigated IL-1beta release under various conditions including hypobaria, normobaric 
hypoxia, and hypobaric hypoxia. An altitude of 6069 m was simulated in a hypobaric chamber. Only after 
stimulation with LPS changes were found. Only under hypobaria and hypobaric hypoxia, IL-1beta levels 
decreased significantly; normobaric hypoxia had no influence in IL-1beta plasma levels. This finding leads 
to the conclusion that hypobaria is a crucial stimulus, while hypoxia alone is insufficient to cause changes 
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in IL-1beta levels [10]. The same results were observed by Julian et al.[49], when IL-1beta levels fell below 
detection limits. 
Unlike this study, all other investigators, except Wang et al.[92] , used artificial hypoxic conditions, which 
is not comparable with hypobaric hypoxia in altitude conditions. Cell cultures stimulated with PMA 
(phorbol-12-myristate-13-acetate) were used by the other investigators; however, this study used whole 
blood and couldn´t differentiate the effects by specific cell type. Compared to the short impaired hypoxia 
models, this study had a longer acclimatization to altitude. As already mentioned, the interference prone 
cytokines might cause different results under changed environmental conditions and a field study is not 
comparable to the in vitro conditions [92]. 
Another theory supports the data presented here and explains a physiological reason for a missing 
proinflammatory cytokine response. There is a known inhibitory effect of proinflammatory cytokines, 
mainly IL-1beta, in hypoxic triggered erythropoetin production from hepatocytes[93]. Faquin et al.[53] 
and Ferucci et al.[94] have shown that IL-1beta is a dose dependent and a powerful inhibitor of hypoxia 
triggered EPO production in hepatocytes. One assumption and possible explanation for the missing IL-1 
beta elevation under hypoxia might be due to a physiological adaption to hypoxia from an increase of 
EPO. 
IFNgamma levels decreased from sea level to high altitude level. The data presented here is in agreement 
with the results of Facco et al.[46] that also showed a decrease of IFNgamma plasma levels in acute and 
chronic hypoxia (day 1, day 21 and after returning to sea level) in young female subjects. They also 
differentiated white blood cells and showed a decrease of IFNgamma release from T cells in hypoxia and 
a decrease of CD4 and CD8 T- lymphocytes. Fritzenwanger et al.[45] has also shown that exposure to 
high altitude results in a decrease in IFNgamma plasma levels.  
However, intermittent hypoxia over a period of 10 days, but in an isobaric atmosphere in a mixed 
chamber (Sa02 80% added) did not show a change in plasma levels of IFNgamma[80]. 
The data of this study supports the hypothesis of animal studies and the work of Facco et al. [46] Hypoxia 
downregulates the expression of IFNgamma from T-cells [75]. The findings of this study supports this 
hypothesis as a decrease in lymphocytes at high altitude (51% of white blood cells at sea level and only 
39 % in high altitude) was observed, although the decrease is not statistically significant. 
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In summary, IFNgamma plasma level is decreased by hypoxia, and this is believed to cause an alteration 
in cellular and immunological parameters [46]. 
Data from this study demonstrate a significant elevation of sIL-2ra after exposure to hypobaric hypoxia; 
however IL-2 plasma levels remain unchanged. After a review of the literature, this study is the first 
investigation to examine sIL-2ra in vivo under hypobaric hypoxia conditions. IL-2 plays a crucial role in T-
cell activation and it is known as a T-cell growth factor and a stimulator in the cellular immune response 
[28]. Elevated levels are correlated with the activity of T-cell mediated disease like sarcoidosis. For that 
reason, sIL-2ra is known as marker for T-cell activation and the sIL-2ra serum levels are currently believed 
to be elevated in T- helper cell induced alveolitis [95]. An assumption leads to a possible correlation of 
alveolar hypoxic conditions and a possible consequence for the immune response [95].  
To date no research reports the effect of hypoxia on sIL-2ra and further investigation is needed to explain 
these findings [30]. 
 
6.2. Chemokines under hypoxic conditions 
 
Chemokines in general fulfill proinflammatory and angiogenetic tasks. One assumption of the 
pathogenesis of AMS is an increased brain volume with diminished buffer capacity that leads to 
symptoms of brain swelling. Proinflammatory mediators are known to weaken the blood- brain barrier 
and are also known to be released during a local hypoxic condition, such as a stroke [49, 56, 96]. 
MCP-1 and MIP-1alpha are known to weaken the tight-junctions in the blood-brain barrier during 
hypoxic induced inflammation and induce a leukocyte attraction in the brain parenchyma. MIP-1beta 
was recently detected as an AMS related chemokine [49].  
An elevation in plasma levels was expected as a systemic response to hypoxia probably initiated by 
hypoxia sensitive organs as the lung and the brain [49]. 
In agreement with Patuccini et al. [97] a significant elevation of IL-8 plasma levels in high altitude 
condition was found. 
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After a review of the current literature, there are only a few known in vivo studies. IL- 8 is a chemotactic 
factor and in hypoxic conditions, endothelial cells are able to release IL-8 to trigger the migration of 
neutrophils to the locus of ischemia [60]. It also has angiogenetic properties in tumor growth and 
metastasis [98].  
IL-8 is known to be involved in the pathophysiologic of ARDS as it is responsible for neutrophil migration. 
Elevated IL- 8 levels have been reported in the BAL of ARDS patients and correlate with the severity [99].  
Since HAPE and ARDS are both correlated with elevated levels of IL-8, it is assumed that the ischemic 
focus attracts leukocytes with the help of IL-8. The exact mechanism remains unclear [59].This theory is 
supported by the work of Karakurum et al.[60] who have demonstrated a hypoxic triggered release of 
IL-8 by endothelial cell will cause the migration of neutrophils to the site of ischemia. 
Patitucci et al.[97] measured IL-8 plasma levels at sea level, Mt. Everest base camp (6000m ) and Mt. 
Everest summit (8848m). Plasma levels were elevated 2.4 times in base camp, with normalization of the 
plasma levels in higher altitudes. (5000m , 6000m, 7000m , 8000m) . This finding is in agreement with 
the results measured in this study. Additional evidence was found when a group of Sherpa’s 
demonstrated higher levels of IL-8 than the westerners [97]. The current belief is that participation of IL-
8 in the acclimatization to hypobaric hypoxia is accomplished by the influence in the nfκB pathway for 
gene transcription [97]. 
HIF 1 alpha indirectly implicates the nfκB pathway and the IL- 8 levels are elevated due to it angiogenetic 
properties [97]. In natives living at high altitudes, the increased levels of angiogenetic IL-8 is seen as a 
measurable factor for adaption to high altitude [97]. 
 
MIP-1alpha/1-beta and MCP-1 are predominantly proinflammatory chemoattractants released by 
resting macrophages and monocytes [15,32,34,35]. The role of chemokines under hypoxia in cerebral 
ischemia was first detected by Bona et al.[55] and Cowell et al.[56] and demonstrated elevated MIP-
1alpha concentrations in cerebral hypoxic ischemic lesions after hypoxic events in neonatal rat brains 
[55]. Cerebral microglia and activated monocytes are the source of MIP-1alpha release [55]. In the recent 
findings, MIP-1beta and MCP-1 plasma levels were increased under hypoxic conditions, especially when 
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MIP-1alpha was significantly decreased. The results correlate with the findings of Julian et al. [49]. 
Elevated MIP-1beta plasma levels were concurrent to the development of AMS in AMS sensitive 
probands [49]. Chemokines influence the development of AMS by attraction of macrophages to hypoxic 
brain areas [96]. MIP-1beta also has an influences in the permeability of the brain blood barrier and 
enables leukocyte migration to the brain parenchyma [49].MIP-1alpha plays a role in hypoxic brain injury 
and assists in parenchyma repair after stroke by recruiting monocytes [56].  
Together with the finding of Julian et al. [49] and from an animal study [56] , the elevation of MIP-1beta 
during hypoxic conditions could underline the hypothesis of the development of HAPE. 
During hypoxic conditions, MCP-1 was found to be significantly elevated in this study. 
This is a new finding because there are no known reports of the quantitative measurement of 
chemokines under in vivo conditions in hypobaric hypoxia. Current research is trying to explain the 
function of MCP-1 during different hypoxic condition in tumor growth and in other ischemic scenarios, 
e.g. brain lesions [96]. It is well known that the major role of MCP-1 is recruiting leucocytes to the hypoxic 
areas of the tumor, and can become the main component of the tumor mass. MCP-1 also plays a crucial 
role in tumor biology in tumor growth, angiogenesis, and metastasis [96] Chao et al. [57] has reported a 
coherence of systemic inflammation triggered by alveolar hypoxia through release of MCP-1 from 
alveolar macrophages. MCP-1 is responsible for the contribution of systemic inflammation, triggered by 
local hypoxic conditions in alveolar macrophages [36]. Other mast cells (peritoneal and blood mast cells) 
do not release MCP-1 during hypoxia. That supports the special key position of alveolar macrophages as 
the first cell to detect and respond to hypoxic conditions [56]. 
The key issue in this finding is the release of proinflammatory mediators. In animal studies, TNF-alpha, 
MIP-1beta and MCP-1 where released by alveolar cells [96].These proinflammatory mediators caused 
the activation of systemic inflammation. Many pathophysiologic conditions start with alveolar hypoxia 
that leads to systemic inflammation (e.g. pneumonia, COPD, and high altitude illness). The result of Chao 
et al. [57]which identified MCP-1 as mediator of systemic inflammation triggered by low alveolar pO2 
concentration, and the data presented from this study support the idea of an hypoxia triggered systemic 
inflammation [58]. 
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Further research is necessary to identify pathways of hypoxia induced inflammation and the 
physiological benefit of a proinflammatory situation, especially in the strategy of acclimatization [49, 57, 
58]. 
 
6.3. Anti-inflammatory cytokines under hypoxic conditions 
 
In accordance with Julian et al.[49] and Facco et al.[46] IL-10, IL 1beta and IL-4 were not infected by 
hypobaric hypoxia, however, a significant increase in IL-1ra was seen at high altitude when compared at 
sea level. 
IL-1ra is known as the highly selective antagonist of the IL-1 triggered proinflammatory cytokine 
response. It is released by different immune cells like neutrophils which were found significantly elevated 
after exposure to hypobaric hypoxia in this study. 
According the innovative finding from Julian et al. [49] a correlation with the increase of IL-1ra levels and 
a particular resistance in the development of acute mountain sickness was shown.  
The pathophysiology of AMS assumes an increase in proinflammatory cytokines that interferes with the 
blood-brain-barrier by impairing tight junctions which leads to the development of brain edema [49, 100, 
101]. In animal studies, IL-1ra is known for its neuro- protective properties in cerebral ischemia [102]. IL-
1ra antagonizes the hypoxic triggered IL-1 driven neuroinflammation and accelerates healing after acute 
hypoxia [103].IL-1ra administered to stroke victims may have a beneficial impact on stroke recovery 
[103]. 
In theory, cytokines with the protective role as an anti-inflammatory should be elevated to prevent AMS. 
Julian et al. [49] revealed the anti-inflammatory effect of IL-1ra in the prevention of AMS. Nevertheless, 
it is difficult to explain a complicated pathophysiological process like the multifactorial and 
oligosymptomatic AMS with the change in one single plasma cytokine level.[49] An increase in IL-1ra 
after the first altitude exposure was found, with no change after the second ascent. The effect of high 
altitude acclimatization is the assumed explanation for expected increase in IL-1ra that did not occur in 
additional to altitude boost [54]. 
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In summary, IL-1ra elevation during hypoxia is an interesting finding and further investigation is needed 
to understand the clinical relevance. 
 
6.4. Cytokines and exercise 
 
Exercise under hypoxic conditions at high altitude is more stressful compared to exercise at sea level. In 
theory this additional stressor is expected to have a greater impact on immune function and cytokine 
levels. Hypoxic exercise should have higher influence in cytokine release than hypoxia without exercising 
[39, 40, 104].  
This study investigated if there are changes in pro- and anti-inflammatory cytokine plasma levels after 
physical exercise when compared to resting values and whether changes occur at high altitude when 
compared to sea level. Furthermore, a small group of 4 male probands were exposed to an additional 
ascent to 6035 m. 
Neither the 12 minute exercise protocol at sea level and at high altitude, nor a 12 hour climb from Hidden 
Valley Base Camp (5050m) to Damphus Peak (6035m) and back produced significant changes in cytokine 
levels. However, an elevation in IL-12p40 plasma levels post- exercise was measured at high altitude 
(5050m) conditions. 
The recent reviews of Suzuki et al.[105] and Walsh et al. [67, 68]demonstrated that in the majority of 
the investigations reported in the literature, exercise alone didn´t change IL-1beta, TNF-alpha, and 
IFNgamma plasma levels. 
However, IL-6 and IL-1ra plasma levels are, in general, increased after exercise. The chemokines IL-8, 
MCP-1 as well as MIP-1alpha present conflicting data. The literature reports vary on the plasma levels of 
IL-10 and, to the author’s knowledge, changes to IL-4 levels hasn’t been reported [106]. 
In the recent work, the plasma cytokine levels of IL-6 remain uneffected by exercise in normoxia and 
high altitude. In comparison with the study of Hagobian et al. [107], the study design is similar. The 
differences in Hagobian et al.’s study design is a testing level at a lower altitude (4300 m), with only one 
night to acclimatize (at 1860m) before the first testing day in 4300m . Additionally, another exercise 
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mode (ergometric cycling) was chosen. Carbohydrate supplements and antioxidants were given to the 
probands, with no significant influence in the measured IL- 6 and TNF-alpha levels. Hagobian et al 
[107]reported a significant elevation of IL-6 after exercise 2, 4 and 20 h post exercise (42 times higher 
than at sea level)at the first day in high altitude. In the recent study, the blood sample was taken 180min. 
post exercise after 3 weeks continuous walking to the altitude of 5050m and it is possible that the 
elevation of cytokines seen in Hagobian et al.’s study was missed due to the time of sampling. In 
Hagobians study, the measurement of IL-6 plasma level were made at day 1 (altitude 4300m) and day 
13 at the same altitude. At day 1, IL-6 levels were elevated 42-fold, but the high plasma levels were not 
persisting during the high attitude sojourn. There might be the explanation for our findings. A long 
sejourn under high altitude conditions decrease the plasma levels in IL-6. 
In future investigations, post exercise data needs to be measured more frequently to get a better 
understanding of cytokine distribution [107]. 
It has been reported that hypoxia and exercise induced elevation in plasma cytokine are removed from 
the systemic circulation via a renal elimination pathway to the urine [108]. 
The time of detection of the cytokine elimination product in the urine is variable and depends on the 
time of elevation in the serum [109]. Often cytokines are not detectable in the plasma after a trigger, 
but an elevation in the urine can be found.  
IL-6 which peaks during exercise, (what we couldn´t measure because of the mode of exercise) and 
directly after exercise and it is measureable in the urine about 1 hour after exercise. Different elimination 
times are assumed, but not known, for each of the cytokines. An assumption leads to the conclusion that 
the sampling 180 min. post exercise could be to late for a detection of elevated plasma levels in IL-6.  
That supports the finding of the unchanged cytokine situation, independent of hypoxic environment. In 
the further investigation, sampling time needs to be early after the trigger, because of the short half life 
of cytokines [105, 109-111]. 
In correlation to Hagobian et al. [107], TNF-alpha did not show a change under any condition. The 
antioxidant supplementation had no influence in cytokine plasma levels in the mentioned study. This is 
controversial data. Nieman et al. [112] found lower levels in the anti-inflammatory cytokines IL-10 and 
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IL-1ra and lower cortisol levels and they have shown the expected increase in IL-6 is reduced by ingesting 
carbohydrates [113]. Carbohydrates influence the immune system through an increased blood glucose 
level that cause enhanced fat oxygenation and elevated stress hormone release [113]. The hormone-
pituitary axis exerts its effect through adrenal gland activation causing the release of cortisol, glucose 
and epinephrine which interferes with the release of proinflammatory cytokines [114]. 
The probands in this study also participated in other studies during the research expedition. One study 
was a double blind experiment using carbohydrate supplementation versus placebo. The high caloric 
carbohydrate supplement could have influenced cytokine release and interfered with collected results. 
The current literature has demonstrated cytokine elevation only after extreme exercise (e.g.marathon) 
at sea level [115, 116] According to the latest review of Suzuki et al. the majority of studies have not 
found a change in TNF-alpha after exercise [67, 68, 112]. As we had no change after the step test in sea 
level and at high altitude, in correlation to others, the theory is supported that the mentioned exercise 
isn´t sufficient to trigger a TNF-alpha release.[69, 70, 115, 117]. 
An early proinflammatory cytokine, IL-1beta, wasn´t found to be elevated after exercise in this 
investigation and is in agreement to the latest reports in the literature [19, 20, 108]. 
It has been shown that there is no correlation in IL-1beta secretion with changes in mode and intensity 
of exercise. Sprenger at al.[108]found no change in IL-1beta after a strenuous 20 Km marathon race. 
However, there is conflicting data showing an increase of IL-1beta in the muscle after a downhill running 
race. That supports the theory of local cytokine release from the contracting muscle [118]. During 
hypoxia, Wang et al.[92] performed an exhausting exercise test using a bicycle ergometer and 
demonstrated an increase of IL-1 beta; however, plasma levels of IL-1beta decreased with exercise under 
severe hypoxic conditions. 
Since IL-6 and IL-10 were increased post-exercise and post-hypoxia, a buffer effect of anti-inflammatory 
cytokines was proposed [70]. Strangely, IL-1beta, one of the early proinflammatory cytokines was only 
increased after eccentric exercise [92].No effect in plasma levels of IL-6 and IL-10 was seen after 
submaximal exercise [20]. It is assumed that the release of IL-1beta from the working muscle is stopped 
by the anti-inflammatory effect of IL-6 and IL-10. This study could not show a change in IL-6, IL-10 or IL-
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1 beta, but this observation correlates with the current thinking that the inflammatory cytokines IL-1beta 
and TNF-alpha are not stimulated in the classical cascade after exercise and under hypoxia [70].  
Contrary to the findings presented in this study, Wang et al. [92]and Smith at al. [119]found a decrease 
in IL-1beta after exercise.  
This study’s design may explain the observed difference. Perhaps the rapid excretion of IL-1beta into the 
urine is could the reason why no change in IL-1beta in the serum after exercise was detected. 180min. 
after excersice [104, 108]. 
Another reason might be that the local production of IL-1beta from the exercising muscle could not be 
detected in the blood [118].  
IL-6’s role to increase the immune response has been assumed for a longtime and it is known to be the 
first cytokine to increase during exercise and up to a100-fold increase in plasma levels can be detected 
after exercise [104, 112, 115]. IL-6 was almost augmented in all exercise studies in literature 
[120].However, there is no evidence in the literature to support the notion that IL-6 is produced as a 
modulator of the immune system in the classical acute phase response [120]. The exercise cascade 
begins with a peak in IL-6 elevation during exercise and then a rapid decrease; this is followed by increase 
of IL-1ra, IL-8, MIP-1alpha and MIP-1beta [22]. It differs from the classical immune cascade because TNF-
alpha is mostly unchanged in any post-exercise condition and IL-6 and TNF-alpha are initiators of the 
classical proinflammatory cascade. The elevated plasma levels of IL-6 and TNF-alpha are likely due to 
metabolic demands [22, 67, 68, 104]. 
Immune cells are not the only source of IL-6. Contracting muscle has also been shown to release IL-6 [67, 
68, 120].In addition to IL-6’s immune function, it is postulated to have a metabolic role to modulate 
glucose uptake and fat oxygenation in the working muscle [22, 115].  
IL-6 is also known to inhibit the production of TNF-alpha and IL-1 in combination with exercise that 
results in an anti-inflammatory effect on the exercise [115].  
The reason why no changes of IL-6 levels were measured in this investigations could be due to the time 
of sampling. It has been reported that according to the mode of exercise, either eccentric (lengthening 
contraction) or concentric (shortening contraction), levels of IL-6 can vary [20]. In concentric training, 
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the levels of IL-6 decrease within a few hours post exercise, but with, eccentric exercise plasma levels IL-
6 remain elevated for a few days [20]. A correlation of work intensity and IL-6 release by muscle 
contraction is assumed [20, 115] [121]. 
In this work the levels of anti-inflammatory cytokines did not show a change after exercise in normoxia 
and hypobaric hypoxia. 
No change in IL-1ra plasma level was found after exercise. These results correlate with those of Hirose 
at al.[20] There is, however, conflicting data reported in the literature. Ostrowski et al.[104] and 
Schobensberger et al. [122]have demonstrated an elevation in IL-1ra after a marathon race .Similar to 
this study design, an ultramarathon in the Alps was performed (67 km in distance at a maximum height 
of 2700m). Compared to the mode of exercise use in this study, both used a more strenuous exercise. 
The reported running time of the participants was between 2 hours 40 minutes to 8 hours (average was 
3 hours 27 minutes). In the study presented here, the participants had an ascent of 15 days allowing for 
acclimatization and a positive training effect that could be responsible for the observed unchanged 
plasma level. 
It is assumed that extensive exercise releases more cytokine from more micro-trauma muscle damage. 
During exercise, blood flow to the internal organs is reduced. Effective renal plasma flow is reduced and 
is related to the intensity of exercise and renal blood flow may decrease to 25% of the resting flow. The 
redistribution in blood flow influences the cytokine clearance and augments cytokine level in prolonged 
exercise [20, 105]. 
In summary, there was no change in plasma cytokine levels in pro- and anti-inflammatory cytokines after 
a standardized maximal step test over a 12 minutes except for an increase of IL-12p40 post-exercise at 
high altitude. 
Reasons for the unchanged cytokines levels are multifactorial. The mode of exercise is important-
eccentric or concentric training, the amount of contracting muscle mass and the duration of training 
influence the cytokine release [20, 115, 121]. Another confounding factor is the timing of blood sampling. 
The urine clearance is different for every cytokine and depends on the renal blood flow which is reduced 
during maximum exercise to the benefit of a better muscle perfusion [20, 105]. 
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The 15-day long ascent to the altitude of 5050 m by continuous walking on an uphill gradient served as 
submaximal training and allowed for a metabolic acclimatization to hypoxia and hypoxic exercise and is 
assumed to have influence the data results. There is most probably a trainings effect in continuous 
walking over 3 weeks and a slow acclimatization to hypoxia, that explains the unchanged plasma cytokine 
situation. Further investigation is needed to demonstrate the metabolic role of proinflammatory 
cytokines during exercise. Additional studies are needed to measure metabolic parameters as blood 
glucose, cortisol and stress hormone levels. 
 
6.5. Summary and further directions 
 
This investigation is one of the most comprehensive biomarker studies for cytokines and chemokines 
under in vivo conditions. 
It included pro- and anti-inflammatory cytokines and chemokines in both normobaric and hypobaric 
hypoxia and includes markers (that to the best of this author’s knowledge) that have not been reported 
under these conditions like sIL-2ra and IL-12p40. The study design had data collection at sea level and in 
high altitude, and an additional second higher altitude exposure with a standardized exercise test as 
additional stressor and trigger for cytokine and chemokine release. Compared to preceding 
investigations, this expedition offered a sufficient and significant amount of probands that enhances the 
validity of data. 
This study has shown that hypoxia triggers an increase in TNF-alpha and most of the chemokines, with 
the only exception being the decrease in MIP-1alpha.  
TNF-alpha is known as the key cytokine of the classical proinflammatory cytokine cascade and was 
elevated without a change in IL-6 or IL-1beta levels. It challenges the question if TNF-alpha is elevated 
because of a pathophysiological process like the development of AMS (25 % of the probands suffered 
temporarily from AMS) since it is known that other hypoxic triggered processes, such as OSAS, COPD, 
right ventricular hypertrophy and remodeling [16, 50], or from the interruption in homeostasis due to 
hypoxia as an immune system response [80]. 
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Another remarkable result is the increased plasma level in IL-1ra with its protective anti-inflammatory 
properties. This finding supports the hypothesis of a protective effect of IL-1ra in the development of 
AMS [49]. Additionally, IL-8 was elevated in hypoxia. In correlation with the recent literature, this finding 
supports the hypothesis of IL-8 involvement in the acclimatization to high altitude and the increase 
elevation observed in natives. Further research is necessary to identify the nuclear mechanism that 
influences EPO release triggered by IL- 8. 
The remaining chemokines are well known to be elevated in hypoxic conditions such as after a stroke. 
This interesting finding needs further investigation to explain the role of chemokines in the development 
of AMS and especially HAPE, by their interference in the blood brain barrier [103]. 
A new finding is the increase of sIL-2ra which can serve as a marker for T cell activity during hypoxia. 
All cytokines did not show any change after exercise in sea level, high altitude and in an additional ascent 
over 6000 m. A possible explanation is, that the mode of exercise is not a sufficient trigger for cytokine 
release. The unchanged cytokine situation in sea level conditions underlines this assumption. 
Another explanation is that the probands were already acclimatized from the 15 day ascent to 5050 m 
and there was a trainings effect by continuous walking.[97] 
Further investigations are needed to explain the physiological meaning of changes to cytokine levels 
during acclimatization, adaption to hypoxic conditions, protection of the homeostasis and for future 
clinical applications of this knowledge for the pathophysiological process of other hypoxic conditions as 
stroke, pneumonia, COPD , lung fibrosis and sepsis.
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